Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleSpecial Section on New Opportunities in Targeting WNT Signaling – Minireview
Open Access

Wnt Signaling and Drug Resistance in Cancer

Zheng Zhong and David M. Virshup
Molecular Pharmacology February 2020, 97 (2) 72-89; DOI: https://doi.org/10.1124/mol.119.117978
Zheng Zhong
Department of Physiology, National University of Singapore, Singapore, Singapore (Z.Z.); Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore (Z.Z., D.M.V.); and Department of Pediatrics, Duke University, Durham, North Carolina (D.M.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zheng Zhong
David M. Virshup
Department of Physiology, National University of Singapore, Singapore, Singapore (Z.Z.); Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore (Z.Z., D.M.V.); and Department of Pediatrics, Duke University, Durham, North Carolina (D.M.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David M. Virshup
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Wnts are secreted proteins that bind to cell surface receptors to activate downstream signaling cascades. Normal Wnt signaling plays key roles in embryonic development and adult tissue homeostasis. The secretion of Wnt ligands, the turnover of Wnt receptors, and the signaling transduction are tightly regulated and fine-tuned to keep the signaling output “just right.” Hyperactivated Wnt signaling due to recurrent genetic alterations drives several human cancers. Elevated Wnt signaling also confers resistance to multiple conventional and targeted cancer therapies through diverse mechanisms including maintaining the cancer stem cell population, enhancing DNA damage repair, facilitating transcriptional plasticity, and promoting immune evasion. Different classes of Wnt signaling inhibitors targeting key nodes of the pathway have been developed and show efficacy in treating Wnt-driven cancers and subverting Wnt-mediated therapy resistance in preclinical studies. Several of these inhibitors have advanced to clinical trials, both singly and in combination with other existing US Food and Drug Administration–approved anti-cancer modalities. In the near future, pharmacological inhibition of Wnt signaling may be a real choice for patients with cancer.

SIGNIFICANCE STATEMENT The latest insights in Wnt signaling, ranging from basic biology to therapeutic implications in cancer, are reviewed. Recent studies extend understanding of this ancient signaling pathway and describe the development and improvement of anti-Wnt therapeutic modalities for cancer.

Introduction

Wnt signaling is an evolutionarily conserved signaling transduction pathway that plays important roles in embryonic development and adult tissue homeostasis. Dysregulated Wnt signaling causes human cancers, and an increasing number of studies reveal that elevated Wnt signaling contributes to drug resistance in cancer therapy. Given the core role of Wnt signaling in multiple cancers, the Wnt pathway has been one of the hottest targets of drug development. Several Wnt pathway inhibitors have been developed and show promising efficacy in treating Wnt-driven cancers and subverting Wnt-mediated therapy resistance in preclinical studies. In this review, we will present an update on recent findings in the Wnt signaling transduction pathway and advances in pharmacological targeting of Wnt signaling. We will focus on the roles of Wnt signaling in cancer drug resistance as well as anti-Wnt signaling-based combination therapies. As multiple Wnt inhibitors are being widely used in preclinical studies and some have advanced to clinical trials, resistance to Wnt blockade is also observed in certain Wnt-dependent normal tissue and cancers. Here we will also summarize the potential mechanisms that confer resistance to Wnt inhibitors.

Wnt Signaling Pathway

Wnt Genes and Proteins.

Wnts are secreted proteins encoded by Wnt genes that are present in all clades of metazoans (Holstein, 2012). The first mammalian Wnt gene, mouse Int-1, was identified in 1982 as a proto-oncogene in the mouse genome whose expression was activated by mouse mammary tumor virus (MMTV) proviral DNA integration leading to mouse mammary cancers (Nusse and Varmus, 1982). The Int-1 gene was subsequently found to be a homolog of the Drosophila Wingless gene that controls segment polarity in fly larval development (Rijsewijk et al., 1987). Therefore, genes of this family are called Wnt as a blend, or portmanteau, of Wingless and Int (Nusse et al., 1991). There are 19 Wnt genes in most mammalian genomes, including the human genome, which can be categorized into 12 subfamilies.

Wnt proteins are 350–400 amino acids in length and ∼40 kDa in size. They contain 22 or 24 conserved cysteine residues that form 11 or 12 intramolecular disulfide bonds that are important for the proper folding of the peptides into functionally active proteins (Macdonald et al., 2014). Wnt proteins undergo post-translational modification after translation. Besides glycosylation, all Wnt proteins require a post-translational modification, the addition of a palmitoleate moiety on a conserved serine residue, catalyzed by a membrane-bound O-acyltransferase called PORCN in the endoplasmic reticulum (ER) (Takada et al., 2006; Najdi et al., 2012; Proffitt and Virshup, 2012). This serine residue is conserved in all Wnts across different species except in a distantly related Wnt gene named WntD in Drosophila that regulates NF-κb rather than β-catenin signaling (Fig. 1, A and B) (Ching et al., 2008). The palmitoleation is necessary for the interaction of Wnts with a cargo receptor called WLS that transports Wnts from ER to the plasma membrane (Coombs et al., 2010; Yu et al., 2014). The palmitoleic moiety is also required for direct binding sites for Wnt ligand and its receptor Frizzled on the cell membrane (Fig. 1, C and D) (Janda et al., 2012; Hirai et al., 2019). Previous studies from our group have shown that all assessable human Wnts lost signaling activity when PORCN was knocked out, and this could be rescued by PORCN re-expression (Najdi et al., 2012). Because of the important role of PORCN in Wnt signaling, mutations of the X-linked PORCN gene lead to embryonic lethality in males, and focal defects due to random X inactivation in surviving females (Wang et al., 2007). The O-linked palmitoleate makes Wnt proteins hydrophobic and therefore limits the biologic activity of secreted Wnt proteins to a short range, unlike circulating protein hormones such as insulin that act at a distance.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Wnts are secreted proteins with conserved domains and residues. (A) The consensus modeling of 19 human Wnts. The amino acid sequences of 19 human Wnts were aligned, and the amino acid conservation scores were calculated using The ConSurf Server website (http://consurf.tau.ac.il). The conservation scores were then mapped on the human Wnt3 crystal structure (PDB 6AHY chain B). (B) The consensus modeling of Wnt homologs. The palmitoleation site and Frizzled interaction sites are conserved in all Wnts. 2635 amino acid sequences that are homologs of human Wnt3 were collected from UNIREF90 using the HMMER algorithm. The conservation scores were calculated from 150 amino acid sequences representative of the 2635 sequences using The ConSurf Server website and mapped on the human Wnt3 crystal structure. (C) The crystal structure of human Wnt3 in complex with mouse Frizzled 8 CRD (PDB 6AHY). (D) The Wnt secretion pathway. Wnts are palmitoleated by PORCN in the ER. The palmitoleic moiety (red line) facilitates the interaction of Wnts with the cargo receptor WLS that transports Wnts to the plasma membrane. Multiple routes of Wnt release and extracellular transport including diffusion, exovesicles, and cytoneme-mediated transport have been proposed.

Wnt Receptors.

As secreted but hydrophobic morphogens, Wnts travel locally to bind to cell surface receptors and coreceptors to activate downstream signaling transduction cascades. Wnts have several types of receptors. The best known are the 10 Frizzleds (Fzds) and their coreceptors LRP5/6. However, an increasing number of coreceptors such as GPR124, Reck, and TMEM59 (Zhou and Nathans, 2014; Posokhova et al., 2015; Vanhollebeke et al., 2015; Cho et al., 2017; Gerlach et al., 2018), and alternative receptors including Ror and Ryk have been identified (Niehrs, 2012). The Frizzled receptors are seven-transmembrane proteins and have N-terminal extracellular cysteine-rich domains (CRDs). The crystal structure of Xenopus WNT8 in complex with mouse Frizzled-8 CRD reveals the multiple interacting surfaces of Wnt-Fzd binding, including a hydrophobic groove in the CRD that binds to the hydrophobic palmitoleate on Wnt (Janda et al., 2012). Additional structures have extended these results, suggesting palmitoleate binding serves to dimerize Frizzled CRDs (Hirai et al., 2019; Nile and Hannoush, 2019).

The abundance of cell surface Frizzled proteins is regulated by post-translational modification. Recent studies identified two highly homologous Wnt target genes called RNF43 and ZNRF3, encoding two transmembrane RING domain-containing E3 ubiquitin ligases. RNF43 and ZNRF3 can ubiquitinate the cytosolic domain of Frizzleds causing the internalization and degradation of Frizzleds. As Wnt target genes, active Wnt signaling upregulates the expression of RNF43 and ZNRF3, which in turn downregulate the surface Wnt receptors level and the downstream Wnt signaling in a negative feedback loop (Fig. 2, A and B) (Hao et al., 2012; Koo et al., 2012). This RNF43/ZNRF3 mediated membrane clearance of Wnt receptors is tightly regulated by at least two processes. First, the ubiquitin-specific protease 6 (USP6) reverses the effects of RNF43/ZNRF3 by deubiquitinating Frizzleds (Fig. 2C) (Madan et al., 2016b). Second, R-Spondins (RSPO1-4) are secreted protein ligands that bind to the extracellular domains of both RNF43/ZNRF3 and LGR4/5 and lead to their clearance from the membrane (Fig. 2D) (Niehrs, 2012; de Lau et al., 2014).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

The abundance of cell surface Wnt receptors is tightly regulated by RNF43/ZNRF3, USP6, and R-Spondins. (A) RNF43 and ZNRF3 are Wnt/β-catenin target genes. (B) RNF43 and ZNRF3 ubiquitinate the cytosolic domain of Frizzleds causing the internalization and degradation of Frizzleds. (C) USP6 reverses the effects of RNF43/ZNRF3 by deubiquitinating Frizzleds. (D) R-Spondins bind to the extracellular domains of both RNF43/ZNRF3 and LGR4/5 leading to their membrane clearance. Ub, ubiquitin.

The Wnt/β-Catenin Signaling Cascade.

Binding of Wnt ligands to their various receptors can activate different downstream signaling pathways. The Wnt/β-catenin signal transduction (canonical Wnt pathway) is the most well-studied Wnt pathway. β-catenin, encoded by the CTNNB1 gene, plays a central role in this pathway. β-catenin is a dual function protein, involved in both cell-cell adhesion and regulation of gene transcription. At the cell membrane, β-catenin is part of a protein complex that forms the adherens junction, which is fundamental for the maintenance of the epithelial cell layers. Nuclear β-catenin acts as transcriptional regulator. The abundance of β-catenin is tightly regulated by a destruction complex that contains the scaffold protein AXIN, APC (encoded by the well-known tumor suppressor gene adenomatous polyposis coli [APC]), casein kinase 1 alpha (CK1α), and glycogen synthase kinase 3 alpha and beta (GSK3α/β) (Asuni et al., 2006; Doble et al., 2007; Macdonald et al., 2009).

In the absence of Wnt ligands (Fig. 3, left panel), β-catenin is first phosphorylated by CK1α at Ser45, and subsequently phosphorylated by GSK3α/β at Thr41, Ser37, and Ser33 (Amit et al., 2002; Liu et al., 2002). The F-box protein, β-transducin repeats containing protein recognizes and binds to this phosphorylated β-catenin, mediating its ubiquitination by the Skp1, Cullin, F-box E3 ubiquitin ligase complex and subsequent proteasomal degradation (Jiang and Struhl, 1998; Hart et al., 1999; Liu et al., 1999; Winston et al., 1999).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

The canonical Wnt/β-catenin signaling cascade. (Left panel) In the absence of Wnt ligands, β-catenin is phosphorylated, ubiquitinated, and degraded by the β-catenin destruction complex. (Right panel) Binding of Wnt ligands to the receptors relocalizes the destruction complex to the membrane and interferes with its activity. Subsequently, newly synthesized β-catenin accumulates in the cytoplasm and enters the nucleus to regulate gene transcription. Refer to the text for detailed description. DVL, dishevelled.

In the presence of Wnt ligands (Fig. 3, right panel), Frizzleds and the coreceptors LRP5/6 multimerize at the cell surface. This leads to recruitment of the cytoplasmic protein Dishevelled to the cell membrane by interacting with cytoplasmic domains of Frizzleds (Wong et al., 2003; Ma et al., 2019). The Frizzled-bound Dishevelled recruits the AXIN complex through the DIX domains on Dishevelled and AXIN (Schwarz-Romond et al., 2007). GSK3α/β in the AXIN complex initiates phosphorylation of the PPPSP motifs of the LRP5/6 cytoplasmic tail and primes subsequent phosphorylation by CK1s (Zeng et al., 2005). As docking sites, these phosphorylated LRP5/6 PPPSP motifs recruit more AXIN complexes to the cell membrane that further phosphorylate the LRP5/6 PPPSP motifs as a positive feedback loop (Zeng et al., 2008). Collectively, stimulation of Wnt ligands relocalizes the β-catenin destruction complex to the cell membrane. However, the exact mechanism by which this causes β-catenin stabilization remains controversial. Diverse models have been proposed with supporting evidence, including 1) inhibition of GSK3 activity by the phosphorylated PPPSP motif that binds to the GSK3 catalytic pocket as a “pseudo substrate” (Mi et al., 2006; Cselenyi et al., 2008; Piao et al., 2008; Wu et al., 2009), 2) sequestration of GSK3 from the cytoplasm into multivesicular bodies (MVBs) that restricts GSK3′s access to substrates (Taelman et al., 2010), 3) dissociation of the ubiquitination machinery from the β-catenin destruction complex (Li et al., 2012), and 4) degradation of AXIN and disassembly of the destruction complex (Tolwinski et al., 2003). Subsequently, the newly synthesized β-catenin protein can accumulate in the cytoplasm and enter the nucleus to regulate gene transcription. Notably, inhibition of AXIN-bound GSK3 in Wnt signaling is independent of the well-studied AKT-mediated phosphorylation on the Ser21 of GSK3α and Ser9 of GSK3β that inhibits their kinase activity (Ding et al., 2000; McManus et al., 2005; Ng et al., 2009), and inhibition of GSK3 by Wnts also blocks degradation of other GSK3 targets including MYC (Taelman et al., 2010; Madan et al., 2018).

β-Catenin regulates gene expression in large part in a TCF-dependent manner (Schuijers et al., 2014). The TCF/LEF family is a group of DNA-bound transcription factors with cognate binding motif 5′-AGATCAAAGG-3′. They recruit Groucho family transcriptional repressors to inhibit gene transcription in the absence of β-catenin. When Wnt is present, β-catenin is stabilized and enters the nucleus, binds to TCF, and converts TCF into a transcriptional activator. However, there is a subset of β-catenin transcriptional targets that do not require TCF/LEF factors for their regulation. In these loci, β-catenin interacts with other factors such as MyoD and FOXO to regulate gene transcription (Fig. 3, right panel) (Doumpas et al., 2019).

The direct Wnt target genes are defined as genes with the conserved TCF binding sites that functionally influence gene transcription. Most Wnt target genes are cell type and developmental stage specific, indicating their promoters are subject to additional tissue-specific regulation (Nakamura et al., 2016). Many of these Wnt/β-catenin targets such as MYC and cyclins regulate core biologic processes such as ribosome biogenesis and cell cycle progression (Madan et al., 2018). It is also interesting that a number of the more robust Wnt target genes are themselves negative regulators of Wnt signaling. These include AXIN2, RNF43, ZNRF3, and NOTUM. As described previously, RNF43/ZNRF3 negatively regulate the Frizzleds level on the cell surface (Fig. 2, A and B) (Hao et al., 2012; Koo et al., 2012). NOTUM is a palmitoleoyl-protein carboxylesterase that can remove the palmitoleic group on Wnt ligands (Kakugawa et al., 2015). As this palmitoleic group is necessary for the interaction of Wnt ligand and receptor, Notum inactivates the function of Wnt ligands. These multiple negative feedback mechanisms guarantee that the Wnt signaling is precisely regulated and kept at the just right level.

β-Catenin Independent Wnt Signaling Pathways.

β-Catenin–independent Wnt signaling is defined as Wnt- or Frizzled-initiated signaling that is independent of TCF/β-catenin–mediated transcription. These “noncanonical” Wnt signaling pathways are diverse and their role in mammals is less well understood. Some Wnts such as Wnt5a and Frizzleds are involved in the regulation of intracellular calcium levels and planar cell polarity (Kikuchi et al., 2012). Some Wnts can bind to receptor tyrosine kinases such as ROR2 and RYK to activate downstream signaling leading to, e.g., cytoneme extension (Mattes et al., 2018). Notably, one established effect of Wnt5a is antagonism of the canonical Wnt/β-catenin signaling (Ishitani et al., 2003; Topol et al., 2003; Mikels and Nusse, 2006). The specific signaling pathway regulated by individual Wnt ligand is also based on the specific receptors existing on the cell surface and is cell type and developmental stage dependent (Semenov et al., 2007; Najdi et al., 2012).

Roles of Wnt Signaling in Development and Adult Tissue.

The Wnt signaling pathway is evolutionarily conserved across various species from sponges to fruit flies to human beings (Loh et al., 2016). As shown by both naturally occurring and experimentally induced loss-of-function and gain-of-function mutations in many species, Wnt signaling plays important roles in both embryonic development and in maintaining adult tissue homeostasis.

The first Wnt gene, wingless, was identified in Drosophila. As the name suggests, the first mutant of wingless gene displayed a phenotype of transformation of wing structures into thoracic notal structures. It was also first found in Drosophila that Wnt is critical for the establishment of anterior-posterior polarity during embryonic segmentation (Swarup and Verheyen, 2012). In vertebrates, Wnt signaling also plays a key role in controlling body axis formation. Wnt signaling can induce secondary dorsal structures when misactivated in early Xenopus embryos. This axis duplication assay has been widely applied to functionally test a gene candidate’s effect on the β-catenin–dependent Wnt signaling pathway. In mice, genetic studies have shown that Wnt signaling is required for gastrulation, and Wnt3, Lrp5/6, and β-catenin knockouts generated similar phenotypes (Wang et al., 2012). In summary, Wnt signaling controls axis patterning, cell fate specification, cell proliferation, and cell migration in embryonic development.

In healthy adult tissue, one of the most important roles of Wnt signaling is to maintain the adult stem cells. Using lineage tracing strategies, the Wnt target gene Lgr5 has been demonstrated to mark stem cells, first in the intestine (Barker et al., 2007) and then in several other tissues including stomach, pancreas, liver, kidney, ovarian epithelium, mammary gland, hair follicle, inner ear, and taste buds (Leung et al., 2018).

The intestine is one of the best-studied examples of Wnt signaling and stem cell maintenance. The small intestinal epithelial layer is one of the most continuously proliferative tissues in the body and undergoes self-renewal every 3–5 days. It has a crypt-villus structure (Clevers, 2013). Villi are protrusions of the simple columnar epithelium that extend into the gut lumen. Crypts are invaginations of the epithelium that surround the base of each villus. One set of intestinal stem cells (also called crypt base columnar cells) are located at the base of the crypt, surrounded by the Paneth cells. These stem cells then give rise to the transit amplifying cells, which are rapidly dividing committed progenitor cells that differentiate into all the mature cell types of the epithelium. The mature differentiated cells move upward from the crypt region to the villus and are finally shed as part of the self-renewal process of the intestinal epithelium.

As mentioned previously, the Wnt/β-catenin target gene Lgr5 is exclusively expressed in the crypt base columnar cells, indicating active Wnt signaling in the intestinal stem cells. As a coreceptor for the RSPOs, LGR5 helps to sequester RNF43/ZNRF3 and upregulates the cell surface Frizzled/LRP levels (Fig. 2D). This may work as a positive feedback loop to further enhance the Wnt signaling in these stem cells. There are additional diverse Wnt ligands expressed in the crypt-villus axis that may help regulate differentiation into other cell types (Gregorieff et al., 2005). Paneth cells reside adjacent to the intestinal stem cells at the base of the crypt and are known for expressing several Wnts, including Wnt3. Wnts secreted by Paneth cells can support the ex vivo organoid growth from purified intestinal epithelial cells (Sato et al., 2011). However, one study from our group showed that mice lacking epithelial Wnt activity by genetic ablation of Porcn in the intestinal epithelium had normal intestinal homeostasis as well as normal intestinal regeneration capability after radiation injury, indicating that epithelial Wnts (including Wnts secreted by Paneth cells) are dispensable for these processes (Kabiri et al., 2014). Recently, our group identified the PDGFRα+ pericryptal stromal cells as the critical source of Wnts and RSPO3 for the intestinal stem cells in vivo (Greicius et al., 2018). And three other studies identified stromal cells marked by FOXL1+ (Aoki et al., 2016; Shoshkes-Carmel et al., 2018) and GLI1+ (Degirmenci et al., 2018), respectively, that form the essential Wnt-secreting niche for the stem cells in the gut. Notably, there is significant but incomplete overlap among the PDGFRα+, FOXL1+, and GLI1+ stromal cells (Greicius and Virshup, 2019).

Importantly, Wnt/β-catenin signaling represses proliferation of the intestinal stem cells. It is known that high Wnt/β-catenin signaling, marked by nuclear β-catenin accumulation and β-catenin target gene expression, is largely restricted to the intestinal stem cells in the crypt base, whereas the highly proliferative transit amplifying cells lack Wnt/β-catenin signaling. Instead, it is well established that the EGFR/RAS/MAPK signaling drives active proliferation in the intestine (Biteau and Jasper, 2011; Jin et al., 2015). One recent study found that Wnt inhibition by PORCN inhibitor induced an initial burst of proliferation of the intestinal stem cells due to conversion of the stem cells into the transit-amplifying cells with a loss of stem cell self-renewal (Kabiri et al., 2018). This is driven by activation of the Wnt-suppressed MAPK signaling. And this will eventually lead to intestinal crypt ablation as the transit-amplifying cells differentiate and stem cells get depleted. Collectively, these findings indicate that the role of Wnt signaling in the intestinal stem cell niche is to maintain the stemness and inhibit differentiation rather than to promote the stem cell proliferation (Greicius and Virshup, 2019).

Aberrant Wnt Signaling in Cancer and Pharmacological Targeting of Wnt Signaling

Common Alterations of Wnt Pathway Components in Cancer

The first mammalian Wnt gene, Int-1, was identified because its overexpression caused mouse mammary cancer (Nusse and Varmus, 1982). The first evidence that aberrant Wnt signaling caused human cancer came from studies of hereditary colorectal cancer. In 1991, three groups independently found that the APC gene is mutated in the hereditary colon cancer syndrome, familiar adenomatous polyposis, as well as in many cases of the sporadic colorectal cancer (Groden et al., 1991; Kinzler et al., 1991; Nishisho et al., 1991). Subsequent studies showed that loss-of-function mutations in the APC gene lead to inappropriate stabilization of β-catenin and constitutive transcriptional activation by the β-catenin/TCF complex (Rubinfeld et al., 1996; Korinek et al., 1997; Morin et al., 1997). In agreement with the β-catenin phosphorylation/degradation model (Liu et al., 2002), point mutations in the N-terminal Ser/Thr phosphorylation sites of β-catenin that prevent its degradation were found in a subset of colorectal cancer with wild-type APC gene (Morin et al., 1997).

Aberrant activation of Wnt/β-catenin signaling is not restricted to colorectal cancer. Similar alterations in β-catenin, APC, and AXIN1 are found in liver cancer cases (de La Coste et al., 1998; Anastas and Moon, 2013). A growing series of activating mutations in the downstream components of the Wnt signaling pathway have also been reported in various other cancer types, including cancers originating in stomach, pancreas, ovary, endometrium, kidney, adrenal gland, biliary tract, pituitary, and soft tissues (Table 1). Researchers have also developed mouse models that confirm the tumorigenic effect of hyperactive Wnt signaling (Colnot et al., 2004; Taketo and Edelmann, 2009; Koo et al., 2012).

View this table:
  • View inline
  • View popup
TABLE 1

Common genetic alterations of Wnt pathway components in human cancers

Mutations that activate Wnt/β-catenin signaling fall into two broad categories: Wnt dependent and Wnt independent. Mutations in APC, AXIN1, and CTNNB1 that stabilize β-catenin uncouple the downstream Wnt signaling from the upstream Wnt ligands, which means that β-catenin–dependent transcription is constitutively activated regardless of whether the Wnt ligands and receptors are present or not. More recently, studies from several groups identified activating mutations that are Wnt dependent (Table 1). As described in the previous section, the Wnt receptors (Frizzleds and LRPs) are tightly regulated by two homolog E3 ubiquitin ligases (RNF43/ZNRF3) and Wnt agonists (RSPOs). As a negative feedback mechanism, high Wnt signaling upregulates the expression of RNF43/ZNRF3, which leads to the membrane clearance of Wnt receptors and quenches the upstream Wnt signaling (Fig. 2, A and B). Inactivating mutations of RNF43 and ZNRF3 were first reported in pancreatic and adrenocortical carcinomas, respectively, and subsequently seen in cancers originating in other tissues including esophagus, stomach, biliary tract, large intestine, endometrium, and ovary (Wu et al., 2011; Assié et al., 2014; Giannakis et al., 2014; Madan and Virshup, 2015). Conversely, RSPOs inhibit the activity of RNF43/ZNRF3 (Fig. 2D), and gain-of-function translocations of RSPO2 and RSPO3 were identified first in a subset of patients with APC wild-type colorectal cancer (Seshagiri et al., 2012) and subsequently also identified in several other cancer types (Cardona et al., 2014; Li et al., 2018; Picco et al., 2019). Either loss of function of RNF43/ZNRF3 or gain of function of RSPO2/3 increases the surface levels of Frizzleds and LRPs and makes cells harboring these alterations highly sensitive to low levels of Wnt ligands.

In addition, DNA methylation–mediated epigenetic silencing of genes encoding secreted frizzled-related proteins and Dickkopf-related proteins that are negative regulators of Wnt signaling are common in colorectal, breast, gastric, and ovarian cancers (Caldwell et al., 2004; Suzuki et al., 2004; Veeck et al., 2006, 2008; Yu et al., 2009; Zhu et al., 2012).

Targeting the Wnt Pathway in Cancer

Because of the core role Wnt signaling plays in several human cancers, it has been one of the hottest targets in cancer therapeutics. Multiple inhibitors targeting the Wnt pathway have been developed, and a number have advanced to clinical trials (Table 2).

View this table:
  • View inline
  • View popup
TABLE 2

Inhibitors of the Wnt signaling and their effects in cancer

Loss-of-function mutations of APC/AXIN1 or activating mutations of β-catenin represent the most common genetic alterations that constitutively activate Wnt/β-catenin signaling in human cancers (Table 1). As mentioned previously, these downstream mutations uncouple β-catenin signaling from the upstream Wnt ligand stimulation. Therefore, blocking Wnt/β-catenin signaling in these cancers requires inhibitors targeting downstream in the pathway. In many cases of colorectal cancer, the truncated APC still can functionally mediate β-catenin degradation in the AXIN-containing destruction complex, albeit with a weakened capability (Voloshanenko et al., 2013). In this setting, an increase in AXIN protein can restore β-catenin degradation. This can be achieved by inhibition of tankyrases TNKS1 and TNKS2, ADP ribosyltransferases that normally drive degradation of AXIN and other proteins (Huang et al., 2009; Riffell et al., 2012). Several tankyrase inhibitors such as XAV939 have been developed and show significant Wnt/β-catenin signaling suppression and anticancer effect in Wnt-driven cancer with APC mutations (Chen et al., 2009; Huang et al., 2009; Waaler et al., 2011, 2012; James et al., 2012; Lau et al., 2013; Okada-Iwasaki et al., 2016; Thomson et al., 2017). Activation of CK1α in the destruction complex similarly causes β-catenin degradation. This was first demonstrated with pyrvinium (Thorne et al., 2010) and more recently with more selective molecules (Li et al., 2017).

Another approach to inhibiting downstream β-catenin signaling is to block the interaction of β-catenin with TCF/LEF or associated transcriptional coactivators such as CBP/p300. A series of small molecule inhibitors called “inhibitor of β-catenin responsive transcription” (iCRT) inhibits the interactions between β-catenin and TCF4 and thereby suppresses the transcriptional activity of β-catenin (Gonsalves et al., 2011). The small molecule inhibitor ICG-001 binds specifically to CBP but not the related transcriptional coactivator p300, thereby disrupting the interaction of CBP with β-catenin. In preclinical studies, ICG-001 can significantly suppress β-catenin/CBP–mediated transcriptional activation or repression and shows anti-tumorigenesis effects (Emami et al., 2004; Arensman et al., 2014; Gang et al., 2014). Its active enantiomer PRI-724 has entered early phase clinical trials for treating patients with advanced tumors (Ko et al., 2016; El-Khoueiry et al., 2017). Similarly, another small molecule inhibitor called Windorphen selectively targets the association of β-catenin with the transcriptional coactivator p300 but not CBP (Hao et al., 2013).

Upstream Inhibitors.

Hyperactive Wnt signaling in cancer can also result from elevated surface Wnt receptor abundance due to alterations in RNF43/ZNRF3 or RSPOs. To suppress Wnt signaling in such cases, studies have focused on the upstream components of the Wnt pathway that include Wnt ligand secretion, Wnt receptor turnover, and Wnt ligand-receptor interactions. As described previously, mammalian Wnts require palmitoleation by PORCN to be secreted. Therefore, small molecule inhibitors targeting PORCN can block secretion of all Wnts and thereby suppress the downstream signaling. Notably, PORCN inhibitors can shut down both canonical and noncanonical Wnt signaling. Several PORCN inhibitors have been developed. They showed potent suppressive effect in preclinical models of Wnt-addicted cancers (Jiang et al., 2013; Liu et al., 2013; Proffitt et al., 2013; Madan et al., 2016; Bhamra et al., 2017; Li et al., 2018) and have entered clinical trials. In addition, neutralizing antibodies targeting Wnt receptors (Frizzleds and LRPs) and agonists (RSPOs) and soluble Fzd-based decoy receptor of Wnt ligands have been developed by different groups. Some of these have also entered clinical trials (Ettenberg et al., 2010; Gurney et al., 2012; Madan and Virshup, 2015; Chartier et al., 2016; Jimeno et al., 2017; Steinhart et al., 2017).

Wnt Signaling Mediated Resistance in Cancer Therapy

Wnt Signaling in Cancer Stem Cell.

Stem cells are defined as multipotent cells that can perpetuate themselves through self-renewal and can also differentiate into mature cells of a particular tissue type. They are present in many adult tissues and organs and help to maintain the normal tissue architecture (Reya et al., 2001). Over the past two decades, more and more studies have revealed the heterogeneity within a tumor population in various cancer types. The cancer stem cell model is one way to explain the intratumor heterogeneity (Visvader and Lindeman, 2008). Similar to normal stem cells, cancer stem cells refer to a subset of tumor cells that undergo self-renewal while generating differentiated cells that comprise the bulk of the tumor. However, compared with the normal tissue stem cells, cancer stem cells proliferate and differentiate aberrantly. Many studies have shown that cancer stem cells are more resistant to traditional chemotherapy and radiotherapy, which could be because of the higher expression of antiapoptotic proteins such as MYC, multidrug resistance genes such as the ATP-binding cassette (ABC) transporters including multidrug resistance (MDR) 1 and MRP1, and more efficient DNA damage repair. Therefore, in many cancers, although chemotherapy or radiotherapy can kill a majority of the proliferating cells leading to tumor shrinkage, the cancer stem cells can survive and lead to cancer relapse. Cancer stem cells were also reported to contribute to tumor metastasis.

Wnt signaling is well-known for regulating stemness in many normal tissues. Several studies have shown that Wnt signaling also plays important roles in maintaining cancer stem cells in various cancer types.

CD34+ bulge stem cells maintain follicular homeostasis in mouse skin. In a mouse cutaneous tumor model induced by chemical carcinogens (DMBA/TPA), CD34+ cells are significantly enriched by 9-fold in the tumor tissues compared with the normal skin. And the CD34+ tumor cells are 100-fold more potent in initiating tumors than unsorted tumor cells in the limiting-dilution transplantation assay, which means this CD34+ population contains the cancer stem cells of this mouse tumor model. It was further shown that Wnt/β-catenin signaling is essential in sustaining the CD34+ cancer stem cell phenotype and that β-catenin deletion leads to the loss of CD34+ cancer stem cells as well as complete tumor regression (Malanchi et al., 2008).

In pancreatic cancer, a small population of cancer cells with high intrinsic Wnt/β-catenin signaling showed properties indicative of cancer stem cells, including higher tumor-initiating capacity and drug resistance, whereas cancer cells with low Wnt activity expressed markers of differentiation. In these tumors, RSPO2 was shown to enhance Wnt/β-catenin signaling to confer stemness traits to susceptible pancreatic cancer cells (Ilmer et al., 2015).

In mouse and human lung adenocarcinomas, two distinct cell subpopulations were identified, one with high Wnt/β-catenin signaling and the other forming the niche that provides the Wnt ligands. The Wnt responding cells expressed the stem cell marker LGR5 and had increased tumor propagation capacity. They comprised a small minority of the tumor but could give rise to the other cell populations of the tumor bulk. The evidence suggests that these cancer cells with active Wnt signaling have features of normal tissue stem cells. Genetic and pharmacological perturbation of Wnt signaling in this model significantly suppressed tumor progression (Tammela et al., 2017).

In colorectal cancer, even though most of the cancer cases have elevated Wnt/β-catenin signaling due to mutations/alterations in the Wnt pathway components, the Wnt signaling level reflected by β-catenin localization and target genes expression is still very heterogeneous within the tumor. It is reported that high Wnt signaling functionally designates the cancer stem cells in colorectal cancer. These Wnt high tumor cells are located close to stromal myofibroblasts and respond to the myofibroblast-secreted factors to activate β-catenin–dependent transcriptions. Notably, myofibroblast-secreted factors can also restore the cancer stem cell phenotype in more differentiated tumor cells, suggesting that the dynamic stemness in colorectal cancer is not just defined by high Wnt signaling, instead is also orchestrated by the tumor microenvironment (Vermeulen et al., 2010).

Recent studies also revealed the involvement of noncoding RNAs in regulating stemness of cancer cells. Many of the reported noncoding RNAs confer stemness traits to cancer cells through activating Wnt/β-catenin signaling (Zhan et al., 2017). microRNA-146a represses Numb and stabilizes β-catenin to maintain the symmetric division of colorectal cancer stem cells (Hwang et al., 2014). In liver cancer stem cells, the long noncoding RNA lncTCF7 is highly expressed and triggers TCF7 expression by recruiting the SWI/SNF complex to TCF7 promoter, thereby activating Wnt signaling. lncTCF7 is required for the self-renewal and tumorigenic capacity of liver cancer stem cells (Wang et al., 2015). miR-142 promotes mRNA degradation of APC to activate Wnt signaling in breast cancer stem cells (Isobe et al., 2014), whereas miR-582-3p targets mRNAs of Wnt signaling negative regulators AXIN2, DKK3, and SRP1 for degradation to maintain stemness features in non–small cell lung cancer (Fang et al., 2015).

Wnt Signaling Mediated Resistance to Conventional Chemotherapy and Radiotherapy.

Conventional chemotherapy exposes patients with cancer to cytotoxic agents to block proliferation and lead to cell death of rapidly proliferating cells including but not limited to cancer cells. Radiotherapy applies ionizing radiation to tumor tissues, which damages the DNA of cancer cells and leads to cell death. Cancer stem cells are known to be more resistant to traditional chemotherapeutic agents and radiation compared with the non–stem cell populations of the tumor bulk, and thereby may be able to cause cancer relapse after chemotherapy or radiotherapy. It has been discussed in the previous section that Wnt signaling is important in maintaining the cancer stem cells, therefore contributing to therapeutic resistance in several cancer types.

However, the protective effect conferred by Wnt signaling against chemotherapy and radiotherapy is not restricted to cancer stem cells but also applies to the non–stem cancer cell populations. It has been reported in many cancers that the Wnt/β-catenin activity level positively correlates with the resistance to several common chemotherapeutic drugs and radiation. Chemotherapy or radiation can upregulate Wnt signaling, and upregulation of Wnt signaling protects cancer cells from cell cycle arrest or apoptosis. Although this protective effect has been attributed to the downstream effectors of Wnt/β-catenin signaling such as survivin in one study, more generally the underlining mechanism still remains unclear (Watson et al., 2010; Gao et al., 2013; Nagano et al., 2013; Emons et al., 2017). Two recent studies found that elevated Wnt signaling enhanced the DNA damage repair and thereby conferred resistance to the PARP inhibitor olaparib in ovarian cancers (Fukumoto et al., 2019; Yamamoto et al., 2019). This mechanism could also protect cancer cells from DNA damage caused by other conventional chemo agents or radiation. Another study reported that canonical Wnt signaling is activated in therapy-induced senescence of cancer cells and can enhance the tumor initiation capacity of cancer cells released or escaping from senescence (Milanovic et al., 2018). In addition, blockade of Wnt signaling by small molecular inhibitors or antibodies targeting Frizzleds or RSPOs can significantly enhance the toxicity of chemotherapy or radiotherapy or resensitize the resistant tumors to the treatment in many studies. Notably, except for those Wnt-driven tumors, anti–Wnt signaling treatment itself normally does not show potent suppressive effect on tumor growth but can significantly enhance the therapeutic effects of conventional chemotherapeutic agents in combinational treatment, further suggesting that Wnt signaling has a specific role in mediating resistance to chemotherapy (Nagaraj et al., 2015; Chartier et al., 2016; Fischer et al., 2017a,b; Trillsch et al., 2017).

Wnt Signaling Mediated Resistance to Targeted Therapy.

Wnt signaling also confers resistance against more targeted therapies. Prostate cancer is hormone sensitive; therefore, most patients with prostate cancer who cannot be cured by surgery or radiation undergo androgen deprivation therapy. However, the majority of those patients eventually develop lethal metastatic castration–resistant prostate cancer. Some of the resistance is due to intracrine biosynthesis of androgens, which can be blocked by abiraterone acetate/prednisone (AA/P). But there are still many patients who fail to respond to AA/P. A recent clinical study showed that the AA/P nonresponders have more alterations of Wnt pathway components in their tumors, resulting in elevated Wnt/β-catenin signaling. Organoids derived from tumors of the nonresponders are also resistant to AA/P but can be resensitized to AA/P by Wnt pathway inhibition (Wang et al., 2018). This finding is consistent with preclinical study results that show that Wnt/β-catenin signaling can be activated in prostate cancer cells after androgen deprivation to promote androgen-independent growth, and combining antiandrogen agent with a Wnt pathway inhibitor can achieve enhanced growth suppression effect in both androgen-dependent and -independent prostate cancer cells (Wang et al., 2008; Lee et al., 2015). In addition to the canonical Wnt/β-catenin signaling, it is also reported that the noncanonical Wnt signaling is activated by WNT5A and WNT7B in the circulating tumor cells, which mediates resistance to the androgen receptor inhibitor (Miyamoto et al., 2015). Finally, both canonical and noncanonical Wnt signaling are involved in the bone metastases that are common in prostate cancer (Dai et al., 2008; Nandana et al., 2017).

Active Wnt signaling also contributes to resistance to growth factor signaling pathway inhibitors. A high nuclear β-catenin level is associated with resistance to PI3K/AKT/mTOR inhibitors in patients with colorectal cancer (Arqués et al., 2016). Mechanistically, inhibition of PI3K/AKT signaling promotes nuclear accumulation of the proapoptotic tumor suppressor FOXO3a. However, high nuclear β-catenin confers resistance to the FOXO3a-mediated apoptosis and subverts FOXO3a to promote metastasis in colon cancer, which can be reversed by tankyrase inhibition (Tenbaum et al., 2012; Arqués et al., 2016). In preclinical studies, elevated Wnt signaling has been observed in PI3K inhibitor–treated breast cancer cells and BRAF inhibitor–treated colorectal cancer cells. PI3K inhibition promotes the expression of Wnt ligands in breast cancers, whereas BRAF inhibition upregulates β-catenin signaling through activating the focal adhesion kinase in colorectal cancer. Blocking Wnt/β-catenin signaling by tankyrase inhibitor or PORCN inhibitor can significantly enhance the tumor suppression effect of these small molecular inhibitors targeting the growth factor signaling pathways (Tzeng et al., 2015; Solzak et al., 2017; Chen et al., 2018; Solberg et al., 2018). In EGFR-mutated lung cancer, even though EGFR inhibitors are not observed to significantly upregulate Wnt signaling in preclinical studies, Wnt/β-catenin signaling has been shown to drive resistance to EGFR inhibitors in lung cancer cells because tankyrase inhibitor and EGFR inhibitor in combination can synergistically suppress lung cancer cell growth in vitro and in vivo (Casás-Selves et al., 2012; Scarborough et al., 2017).

Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that entered clinical trials for treating acute myeloid leukemia. Two independent studies found that Wnt/β-catenin signaling promotes primary and acquired resistance to BET inhibition in leukemia (Fong et al., 2015; Rathert et al., 2015). Mechanistically, BET inhibitors disrupt the BRD4-chromatin interaction and repress BRD4-dependent transcription of genes such as MYC to suppress cancer progression. However, in the presence of BET inhibitor, β-catenin binds to the promoter regions that are originally occupied by BRD4, and maintains the expression levels of key target genes including MYC. This evidence establishes Wnt/β-catenin signaling as a major driver and candidate biomarker of resistance to BET inhibitors in a subpopulation of leukemia cells that show high transcriptional plasticity.

Recently, two independent studies revealed that Wnt signaling mediates resistance to complete response to Hedgehog signaling inhibition in basal cell carcinoma (BCC) (Biehs et al., 2018; Sánchez-Danés et al., 2018). BCC is the most common malignancy in humans and typically arises due to constitutively activation of Hedgehog signaling. Treatment with Hedgehog signaling inhibitor vismodegib mediates differentiation of BCC cells from a hair follicle stem cell like phenotype to an interfollicular epidermis or isthmus cell fate, and thereby leads to tumor regression (Sánchez-Danés et al., 2018). However, BCC tumors always relapse after vismodegib withdrawal (Tang et al., 2016). It was found that a small population of LGR5+ BCC cells with active Wnt signaling escape from vismodegib-induced differentiation and mediate tumor relapse after treatment discontinuation. Importantly, combining vismodegib with PORCN inhibitor led to the eradication of persistent BCC cells and prevented tumor relapse in mouse models.

Wnt Signaling Mediated Resistance to Immunotherapy.

The roles of Wnt signaling in regulating normal hematopoiesis remains a controversial topic (Staal et al., 2008; Kabiri et al., 2015). However, increasing evidence from recent studies suggests that Wnt/β-catenin signaling drives the primary, adaptive, and acquired resistance to cancer immunotherapy, first in the anti–CTLA-4/PD-1/PD-L1 treatment of melanoma but in other settings as well (Luke et al., 2019). In human metastatic melanoma samples, activation of Wnt/β-catenin signaling correlates with the absence of a T-cell gene expression signature, which reflects a lack of T-cell infiltration. Activation of tumor intrinsic β-catenin signaling suppresses the expression of tumor-cell–intrinsic chemokines such as CCL4, thereby suppressing the recruitment of CD103+ dendritic cells and subsequent activation of CD8+ T-cells (Spranger et al., 2015). The melanoma derived WNT5A can also activate β-catenin signaling in the dendritic cells in a paracrine mode, which upregulates the expression and activity of the indoleamine 2,3-dioxygenase-1 enzyme in local dendritic cells. This promotes the development of tolerogenic dendritic cells and drives the differentiation of regulatory T-cells (Holtzhausen et al., 2015; Zhao et al., 2018). Concurrent inhibition of Wnt/β-catenin signaling enhanced the effect of immune checkpoint inhibitors in select preclinical models.

Anti-Wnt Signaling–Based Combination Cancer Therapies.

As discussed previously, Wnt signaling mediates resistance to several therapeutic modalities in clinical practice as well as multiple anti-cancer agents developed in preclinical studies. Therefore, several drug combination studies combining Wnt-signaling inhibitors with other conventional cytotoxic agents or targeted inhibitors have been tested in preclinical studies and shown improved efficacy. Some of them have advanced into clinical trials. Moreover, recent technical advances in genome sequencing and genetic screening identified a group of genetically defined cancers that are addicted to Wnt signaling and other oncogenic pathways, such as a subset of colon cancers that harbor concurrent mutations in BRAF and RNF43 or RSPOs (Yan et al., 2017) and RNF43-mutant pancreatic cancers that show high dependency on PI3K/mTOR signaling (Zhong et al., 2019). These findings inspired the development of PORCN inhibitor and growth factor pathway inhibitor combinational treatment in preclinical studies and clinical trials. Here, we summarize the drug combinations with Wnt pathway inhibitors for cancer therapy in both preclinical studies and clinical trials (Table 3).

View this table:
  • View inline
  • View popup
TABLE 3

Anti-Wnt signaling-based drug combinations in cancer therapy

Resistance to Wnt Pathway Blockade in Normal Tissue and Wnt-Driven Cancer

As discussed previously, dysregulated Wnt signaling is the driver of a series of genetically defined cancers, and elevated Wnt signaling can mediate resistance to various therapeutic strategies. Therefore, targeting Wnt-signaling pathways has been attracting attention in the field of cancer research for a long time. Researchers have developed different strategies to block Wnt signaling, including antibodies targeting receptors or agonists, PORCN inhibitors, tankyrase inhibitors, etc. These strategies may apply to different cases based on the specific alterations in the Wnt pathway. However, because Wnt signaling also maintains the homeostasis of normal tissue including bone, taste buds, and hair and gut stem cells, one common concern in using Wnt pathway inhibitors is the potential adverse effect on normal tissues with high dependency on Wnt signaling, such as the gastrointestinal tract. Indeed, tankyrase inhibitors have been shown to cause severe toxicity to the gut as well as loss of body weight in mice when used for cancer treatment, which limits the use of tankyrase inhibitors in human patients (Lau et al., 2013). However, surprisingly, PORCN inhibitors can be well tolerated by mice at therapeutic doses for cancer but showing no significant side effect on gut (Liu et al., 2013; Proffitt et al., 2013; Madan et al., 2016). In cancers, even those driven by RNF43 mutations can develop resistance to Wnt blockade because two pancreatic cancer cell lines with the same RNF43 loss-of-function mutation show different sensitivity to PORCN inhibitor. Interestingly, they were isolated from the same metastasis of the same patient, but one cell line is sensitive, whereas the other is resistant to PORCN inhibitor (Jiang et al., 2013). In colorectal cancers with APC mutations, some cell lines are sensitive to tankyrase inhibitors, whereas others are resistant, even though the expression of Wnt target genes can also be repressed by tankyrase inhibitors in the resistant cell lines (Lau et al., 2013). This observation reveals that there are potential mechanisms that mediates resistance to Wnt pathway inhibitors in normal tissues and cancers. Three mechanisms are described here to explain the resistance.

ABC Transporters.

ABC transporters are members of a transport system superfamily. The ABC transporters consist of two ATP-binding domains and two transmembrane domains. These four domains can present in one peptide as a protein or two peptides that form a dimer. The two transmembrane domains typically contain twelve α-helices that form a pore-like structure across the membrane. The ATP-binding domains that have ATPase activity use the energy of ATP binding and hydrolysis to drive the conformational change of the transmembrane domains, thereby energizing the translocation of substrates across the membrane. There are many members in the ABC transporter family that are responsible for uptake or export of various substrates for the cell (Glavinas et al., 2004).

ABC transporters are known to cause the MDR phenotype in cancer cells by pumping diverse anticancer drugs out of the cell. ABCB1 is the most extensively studied ABC transporter related to drug efflux and is also called MDR1 (Robey et al., 2018). Many studies have shown that the expression of ABC transporters is upregulated when tumor cells get resistant to certain drugs, and this always results in multidrug resistance. So far, there is no direct evidence to show that resistance to Wnt pathway inhibitors is because of ABC transporters. However, one recent study from our group shows that in the mouse intestine, the stroma cells that supply Wnts and RSPOs and form the niche for the intestinal stem cells express a subset of ABC transporters, and are therefore resistant to various xenobiotics, including PORCN inhibitors (Chee et al., 2018). This property of the intestinal stroma cells could be due to the unpredictable environment rich in various xenobiotics in the gastrointestinal tract. But it can well explain the differential toxicities that tankyrase inhibitors and PORCN inhibitors have on the gut, as tankyrase inhibitors target the Wnt responding cells (the stem cells) directly, whereas PORCN inhibitors target the Wnt suppling cells, the resistant stroma cells here. This finding provides the rationale for the safety of the gut when using PORCN inhibitors in cancer therapy.

Further Mutations of Wnt Pathway Components.

It is generally accepted that upstream Wnt pathway inhibitors such as PORCN inhibitors are less effective in cancer cells with mutations of downstream Wnt pathway components such as APC mutations, even though it is also reported that Wnt ligands are required to maintain the high levels of Wnt signaling in colorectal cancer cells with APC mutations (Voloshanenko et al., 2013). Besides, it has been observed in many cancer types that inactivating mutations of RNF43/ZNRF3, RSPOs translocation, activating mutations of β-catenin, and loss of APC are almost mutually exclusive, which reflects a rule in tumorigenesis that Wnt/β-catenin signaling only need to be activated in one way or another. However, co-occurrence of mutations in both upstream and downstream Wnt pathway does exist in some rare cases, in which the PORCN inhibitors may not work even though alterations of RNF43/ZNRF3 or RSPOs can be detected. In addition, mutations in downstream components of the Wnt pathway can happen during the long-term treatment with upstream Wnt pathway inhibitors. These resistant clones may be selected by the treatment and become the dominant population of the tumor. This process has been reported in a colorectal cancer cell line VACO6. VACO6 harbors an RSPO3 translocation and is sensitive to the PORCN inhibitor LGK974. However, these cells developed resistance to LGK974 within 3 months when cultured with a sublethal concentration of LGK974. Exome sequencing of the resistant VACO6 clone found truncating mutations in AXIN1 that are absent in the parental cell line (Picco et al., 2017). Interestingly, these truncating mutations have been reported in the Catalogue of Somatic Mutations in Cancer database as cancer-related somatic variants. This study demonstrates that further mutations in downstream components of Wnt signaling can confer secondary resistance to genetically defined cancers that are sensitive to upstream Wnt pathway blockade.

Activation of Other Compensatory Signaling Pathways.

Wnt signaling can mediate resistance to inhibitors of other signaling pathways, especially the growth factor signaling pathways, and so it is not surprising that activation of these growth factor signaling pathways can compensate for Wnt pathway blockade. For example, mTOR signaling is reported to mediate resistance to tankyrase inhibitors in colorectal cancer (Mashima et al., 2017). Mechanistically, most of the pro-oncogenic and anti-oncogenic targets are regulated by more than one pathway. For example, c-Myc, as a Wnt-signaling effector, is regulated at the transcriptional level and post-translational level by Wnt signaling, as well as PI3K/AKT/mTOR signaling, MAPK signaling, etc. Therefore, inhibiting one signaling input can be compensated by other regulators and may have a minimal effect on the output. Notably, in many Wnt-driven cancers, the growth factor signaling pathways are also hyperactivated due to mutations in EGFR, KRAS, BRAF, PI3K, PTEN, etc. Therefore, developing combination drug therapy is a promising solution to maximize the therapeutic effects.

Concluding Remarks

Since the discovery of the first mammalian Wnt gene and its function in the mouse mammary cancer nearly four decades ago, the Wnt-signaling pathway has been extensively investigated worldwide. Although these studies comprehensively revealed the molecular mechanisms and functional effects of the Wnt signaling in normal status and diseases, numerous questions still remain to be answered. Recent findings in the Wnt field continue to extend our understanding of this evolutionarily conserved ancient signaling pathway. As a highlight of this review, an increasing number of studies reveal and confirm the key roles of Wnt signaling in cancer initiation, progression, and drug resistance, inspiring pharmacological targeting of Wnt signaling in patients.

Importantly, increasing knowledge in the Wnt field have facilitated the development of multiple Wnt pathway inhibitors along with rational drug combination strategies. These inhibitors and drug combinations showed promising efficacy in carefully selected preclinical cancer models, and some have advanced to clinical trials. However, considering the important roles of Wnt signaling in maintaining normal tissue homeostasis, the on-target adverse effects of Wnt pathway inhibitors cannot be neglected. Notably, although those upstream Wnt pathway inhibitors including PORCN inhibitors and the anti-Frizzleds antibody advanced to clinical trials and showed manageable side effects, several of the downstream inhibitors such as the tankyrase inhibitors have remained at the preclinical stage, possibly due to the toxicity to the gastrointestinal tract. Therefore, it will be important to both develop more selective inhibitors that have minimal toxicity on normal tissue and also develop synergistic drug combinations so that lower dosages can be used to improve both the therapeutic index and the anticancer efficacy.

Acknowledgments

We acknowledge Sivakumar Parthiban for assistance with the consensus modeling of Wnt proteins. Z.Z. acknowledges Shazib Pervaiz for the supervision on his training. We thank all members of the Virshup laboratory for useful discussions on this work and apologize to our colleagues whose work could not be cited here due to space limitation.

Authorship Contributions

Performed data analysis: Zhong, Virshup.

Wrote or contributed to the writing of the manuscript: Zhong, Virshup.

Footnotes

    • Received September 17, 2019.
    • Accepted November 21, 2019.
  • This study is supported in part by the National Research Foundation Singapore and administered by the Singapore Ministry of Health’s National Medical Research Council under the Singapore Translational Research (STaR) Award Program to D.M.V. Z.Z. was supported by the National University of Singapore (NUS) Research Scholarship. D.M.V. has a financial interest in ETC-159.

  • https://doi.org/10.1124/mol.119.117978.

Abbreviations

AA/P
abiraterone acetate/prednisone
ABC
ATP-binding cassette
AKT
Ak strain transforming
APC
adenomatous polyposis coli
AXIN
axis inhibition protein
BCC
basal cell carcinoma
BET
bromodomain and extra terminal protein
BRAF
V-Raf murine sarcoma viral oncogene homolog B
CK1α
casein kinase 1 alpha
CRD
cysteine-rich domain
EGFR
epidermal growth factor receptor
ER
endoplasmic reticulum
EGFR
epidermal growth factor receptor
FOXO
O subclass of the Forkhead family
Fzd
Frizzled
GSK3
glycogen synthase kinase 3
iCRT
inhibitor of β-catenin responsive transcription
MAPK
mitogen-activated protein kinase
MDR
multidrug resistance
MMTV
mouse mammary tumor virus
MYC
V-Myc Avian Myelocytomatosis viral oncogene homolog
PARP
poly (ADP-ribose) polymerase
PDGFR
platelet-derived growth factor receptor
PORCN
porcupine
RNF43
ring finger protein 43
RSPO
R-Spondin
TCF/LEF
T-cell factor/lymphoid enhancer-binding factor
USP6
ubiquitin-specific protease 6
Wnt
Wingless and Int
ZNRF3
zinc and ring finger 3
  • Copyright © 2020 by The Author(s)

This is an open access article distributed under the CC BY-NC Attribution 4.0 International license.

References

  1. ↵
    1. Amit S,
    2. Hatzubai A,
    3. Birman Y,
    4. Andersen JS,
    5. Ben-Shushan E,
    6. Mann M,
    7. Ben-Neriah Y, and
    8. Alkalay I
    (2002) Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 16:1066–1076.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Anastas JN and
    2. Moon RT
    (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13:11–26.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Aoki R,
    2. Shoshkes-Carmel M,
    3. Gao N,
    4. Shin S,
    5. May CL,
    6. Golson ML,
    7. Zahm AM,
    8. Ray M,
    9. Wiser CL,
    10. Wright CVE, et al.
    (2016) Foxl1-expressing mesenchymal cells constitute the intestinal stem cell niche. Cell Mol Gastroenterol Hepatol 2:175–188.
    OpenUrl
  4. ↵
    1. Arensman MD,
    2. Telesca D,
    3. Lay AR,
    4. Kershaw KM,
    5. Wu N,
    6. Donahue TR, and
    7. Dawson DW
    (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303–2314.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Arqués O,
    2. Chicote I,
    3. Puig I,
    4. Tenbaum SP,
    5. Argilés G,
    6. Dienstmann R,
    7. Fernández N,
    8. Caratù G,
    9. Matito J,
    10. Silberschmidt D, et al.
    (2016) Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res 22:644–656.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Assié G,
    2. Letouzé E,
    3. Fassnacht M,
    4. Jouinot A,
    5. Luscap W,
    6. Barreau O,
    7. Omeiri H,
    8. Rodriguez S,
    9. Perlemoine K,
    10. René-Corail F, et al.
    (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46:607–612.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Asuni AA,
    2. Hooper C,
    3. Reynolds CH,
    4. Lovestone S,
    5. Anderton BH, and
    6. Killick R
    (2006) GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci 24:3387–3392.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Barker N,
    2. van Es JH,
    3. Kuipers J,
    4. Kujala P,
    5. van den Born M,
    6. Cozijnsen M,
    7. Haegebarth A,
    8. Korving J,
    9. Begthel H,
    10. Peters PJ, et al.
    (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449:1003–1007.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Bhamra I,
    2. Adams N,
    3. Armer R,
    4. Bingham M,
    5. McKeever H,
    6. Phillips C,
    7. Thompson B, and
    8. Woodcock SD
    (2017) Novel porcupine (PORCN) inhibitor RXC004: evaluation in models of RNF43 loss of function cancers. J Clin Oncol 35:e14094.
    OpenUrl
  10. ↵
    1. Biehs B,
    2. Dijkgraaf GJP,
    3. Piskol R,
    4. Alicke B,
    5. Boumahdi S,
    6. Peale F,
    7. Gould SE, and
    8. de Sauvage FJ
    (2018) A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Nature 562:429–433.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Biteau B and
    2. Jasper H
    (2011) EGF signaling regulates the proliferation of intestinal stem cells in Drosophila. Development 138:1045–1055.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Caldwell GM,
    2. Jones C,
    3. Gensberg K,
    4. Jan S,
    5. Hardy RG,
    6. Byrd P,
    7. Chughtai S,
    8. Wallis Y,
    9. Matthews GM, and
    10. Morton DG
    (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64:883–888.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Cardona GM,
    2. Bell K,
    3. Portale J,
    4. Gaffney D,
    5. Moy C,
    6. Platero S,
    7. Lorenzi MV, and
    8. Karkera J
    (2014) Abstract 2408: Identification of R-Spondin fusions in various types of human cancer. Cancer Res 74:2408.
    OpenUrl
  14. ↵
    1. Casás-Selves M,
    2. Kim J,
    3. Zhang Z,
    4. Helfrich BA,
    5. Gao D,
    6. Porter CC,
    7. Scarborough HA,
    8. Bunn PA Jr.,
    9. Chan DC,
    10. Tan AC, et al.
    (2012) Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res 72:4154–4164.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Chartier C,
    2. Raval J,
    3. Axelrod F,
    4. Bond C,
    5. Cain J,
    6. Dee-Hoskins C,
    7. Ma S,
    8. Fischer MM,
    9. Shah J,
    10. Wei J, et al.
    (2016) Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types. Cancer Res 76:713–723.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Chee YC,
    2. Pahnke J,
    3. Bunte R,
    4. Adsool VA,
    5. Madan B, and
    6. Virshup DM
    (2018) Intrinsic xenobiotic resistance of the intestinal stem cell niche. Dev Cell 46:681–695.e5.
    OpenUrl
  17. ↵
    1. Chen B,
    2. Dodge ME,
    3. Tang W,
    4. Lu J,
    5. Ma Z,
    6. Fan C-W,
    7. Wei S,
    8. Hao W,
    9. Kilgore J,
    10. Williams NS, et al.
    (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5:100–107.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Chen G,
    2. Gao C,
    3. Gao X,
    4. Zhang DH,
    5. Kuan S-F,
    6. Burns TF, and
    7. Hu J
    (2018) Wnt/β-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer. Mol Cancer Ther 17:806–813.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Ching W,
    2. Hang HC, and
    3. Nusse R
    (2008) Lipid-independent secretion of a Drosophila Wnt protein. J Biol Chem 283:17092–17098.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Cho C,
    2. Smallwood PM, and
    3. Nathans J
    (2017) Reck and Gpr124 are essential receptor cofactors for wnt7a/wnt7b-specific signaling in mammalian CNS angiogenesis and blood-brain barrier regulation [published correction appears in Neuron (2017) 95:1221–1225]. Neuron 95:1056–1073.e5.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Clevers H
    (2013) The intestinal crypt, a prototype stem cell compartment. Cell 154:274–284.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Colnot S,
    2. Decaens T,
    3. Niwa-Kawakita M,
    4. Godard C,
    5. Hamard G,
    6. Kahn A,
    7. Giovannini M, and
    8. Perret C
    (2004) Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 101:17216–17221.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Coombs GS,
    2. Yu J,
    3. Canning CA,
    4. Veltri CA,
    5. Covey TM,
    6. Cheong JK,
    7. Utomo V,
    8. Banerjee N,
    9. Zhang ZH,
    10. Jadulco RC, et al.
    (2010) WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification. J Cell Sci 123:3357–3367.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Cselenyi CS,
    2. Jernigan KK,
    3. Tahinci E,
    4. Thorne CA,
    5. Lee LA, and
    6. Lee E
    (2008) LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3’s phosphorylation of beta-catenin. Proc Natl Acad Sci USA 105:8032–8037.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Dai J,
    2. Hall CL,
    3. Escara-Wilke J,
    4. Mizokami A,
    5. Keller JM, and
    6. Keller ET
    (2008) Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 68:5785–5794.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. de Lau W,
    2. Peng WC,
    3. Gros P, and
    4. Clevers H
    (2014) The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev 28:305–316.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Degirmenci B,
    2. Valenta T,
    3. Dimitrieva S,
    4. Hausmann G, and
    5. Basler K
    (2018) GLI1-expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells. Nature 558:449–453.
    OpenUrlCrossRefPubMed
  28. ↵
    1. de La Coste A,
    2. Romagnolo B,
    3. Billuart P,
    4. Renard CA,
    5. Buendia MA,
    6. Soubrane O,
    7. Fabre M,
    8. Chelly J,
    9. Beldjord C,
    10. Kahn A, et al.
    (1998) Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95:8847–8851.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Ding VW,
    2. Chen RH, and
    3. McCormick F
    (2000) Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 275:32475–32481.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Doble BW,
    2. Patel S,
    3. Wood GA,
    4. Kockeritz LK, and
    5. Woodgett JR
    (2007) Functional redundancy of GSK-3α and GSK-3β in Wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 12:957–971.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Doumpas N,
    2. Lampart F,
    3. Robinson MD,
    4. Lentini A,
    5. Nestor CE,
    6. Cantù C, and
    7. Basler K
    (2019) TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. EMBO J 38:e98873.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. El-Khoueiry AB,
    2. Ning Y,
    3. Yang D,
    4. Cole S,
    5. Kahn M,
    6. Zoghbi M,
    7. Berg J,
    8. Fujimori M,
    9. Inada T,
    10. Kouji H, et al.
    (2017) A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol 2013;31:2501.
    OpenUrl
  33. ↵
    1. Emami KH,
    2. Nguyen C,
    3. Ma H,
    4. Kim DH,
    5. Jeong KW,
    6. Eguchi M,
    7. Moon RT,
    8. Teo J-L,
    9. Kim HY,
    10. Moon SH, et al.
    (2004) A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected] [published correction appears in Proc Natl Acad Sci U S A. (2004) 101:16707]. Proc Natl Acad Sci U S A 101:12682–12687.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Emons G,
    2. Spitzner M,
    3. Reineke S,
    4. Möller J,
    5. Auslander N,
    6. Kramer F,
    7. Hu Y,
    8. Beissbarth T,
    9. Wolff HA,
    10. Rave-Fränk M, et al.
    (2017) Chemoradiotherapy resistance in colorectal cancer cells is mediated by Wnt/β-catenin signaling. Mol Cancer Res 15:1481–1490.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Ettenberg SA,
    2. Charlat O,
    3. Daley MP,
    4. Liu S,
    5. Vincent KJ,
    6. Stuart DD,
    7. Schuller AG,
    8. Yuan J,
    9. Ospina B,
    10. Green J, et al.
    (2010) Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 107:15473–15478.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Fang L,
    2. Cai J,
    3. Chen B,
    4. Wu S,
    5. Li R,
    6. Xu X,
    7. Yang Y,
    8. Guan H,
    9. Zhu X,
    10. Zhang L, et al.
    (2015) Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling. Nat Commun 6:8640.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Fischer MM,
    2. Cancilla B,
    3. Yeung VP,
    4. Cattaruzza F,
    5. Chartier C,
    6. Murriel CL,
    7. Cain J,
    8. Tam R,
    9. Cheng C-Y,
    10. Evans JW, et al.
    (2017a) WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv 3:e1700090.
    OpenUrlFREE Full Text
  38. ↵
    1. Fischer MM,
    2. Yeung VP,
    3. Cattaruzza F,
    4. Hussein R,
    5. Yen W-C,
    6. Murriel C,
    7. Evans JW,
    8. O’Young G,
    9. Brunner AL,
    10. Wang M, et al.
    (2017b) RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations. Sci Rep 7:15270.
    OpenUrl
  39. ↵
    1. Fong CY,
    2. Gilan O,
    3. Lam EYN,
    4. Rubin AF,
    5. Ftouni S,
    6. Tyler D,
    7. Stanley K,
    8. Sinha D,
    9. Yeh P,
    10. Morison J, et al.
    (2015) BET inhibitor resistance emerges from leukaemia stem cells. Nature 525:538–542.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Fukumoto T,
    2. Zhu H,
    3. Nacarelli T,
    4. Karakashev S,
    5. Fatkhutdinov N,
    6. Wu S,
    7. Liu P,
    8. Kossenkov AV,
    9. Showe LC,
    10. Jean S, et al.
    (2019) N6-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res 79:2812–2820.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Gang EJ,
    2. Hsieh Y-T,
    3. Pham J,
    4. Zhao Y,
    5. Nguyen C,
    6. Huantes S,
    7. Park E,
    8. Naing K,
    9. Klemm L,
    10. Swaminathan S, et al.
    (2014) Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 33:2169–2178.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Gao Y,
    2. Liu Z,
    3. Zhang X,
    4. He J,
    5. Pan Y,
    6. Hao F,
    7. Xie L,
    8. Li Q,
    9. Qiu X, and
    10. Wang E
    (2013) Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. Cancer Lett 336:231–239.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Gerlach JP,
    2. Jordens I,
    3. Tauriello DVF,
    4. van ’t Land-Kuper I,
    5. Bugter JM,
    6. Noordstra I,
    7. van der Kooij J,
    8. Low TY,
    9. Pimentel-Muiños FX,
    10. Xanthakis D, et al.
    (2018) TMEM59 potentiates Wnt signaling by promoting signalosome formation. Proc Natl Acad Sci USA 115:E3996–E4005.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Giannakis M,
    2. Hodis E,
    3. Jasmine Mu X,
    4. Yamauchi M,
    5. Rosenbluh J,
    6. Cibulskis K,
    7. Saksena G,
    8. Lawrence MS,
    9. Qian ZR,
    10. Nishihara R, et al.
    (2014) RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 46:1264–1266.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Glavinas H,
    2. Krajcsi P,
    3. Cserepes J, and
    4. Sarkadi B
    (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27–42.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Gonsalves FC,
    2. Klein K,
    3. Carson BB,
    4. Katz S,
    5. Ekas LA,
    6. Evans S,
    7. Nagourney R,
    8. Cardozo T,
    9. Brown AMC, and
    10. DasGupta R
    (2011) An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA 108:5954–5963.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Gregorieff A,
    2. Pinto D,
    3. Begthel H,
    4. Destrée O,
    5. Kielman M, and
    6. Clevers H
    (2005) Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology 129:626–638.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Greicius G,
    2. Kabiri Z,
    3. Sigmundsson K,
    4. Liang C,
    5. Bunte R,
    6. Singh MK, and
    7. Virshup DM
    (2018) PDGFRα+ pericryptal stromal cells are the critical source of Wnts and RSPO3 for murine intestinal stem cells in vivo. Proc Natl Acad Sci U S A 115:E3173–E3181.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Greicius G and
    2. Virshup DM
    (2019) Stromal control of intestinal development and the stem cell niche. Differentiation 108:8–16.
    OpenUrl
  50. ↵
    1. Groden J,
    2. Thliveris A,
    3. Samowitz W,
    4. Carlson M,
    5. Gelbert L,
    6. Albertsen H,
    7. Joslyn G,
    8. Stevens J,
    9. Spirio L,
    10. Robertson M, et al.
    (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589–600.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Gurney A,
    2. Axelrod F,
    3. Bond CJ,
    4. Cain J,
    5. Chartier C,
    6. Donigan L,
    7. Fischer M,
    8. Chaudhari A,
    9. Ji M,
    10. Kapoun AM, et al.
    (2012) Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA 109:11717–11722.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Hao H-X,
    2. Xie Y,
    3. Zhang Y,
    4. Charlat O,
    5. Oster E,
    6. Avello M,
    7. Lei H,
    8. Mickanin C,
    9. Liu D,
    10. Ruffner H, et al.
    (2012) ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485:195–200.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Hao J,
    2. Ao A,
    3. Zhou L,
    4. Murphy CK,
    5. Frist AY,
    6. Keel JJ,
    7. Thorne CA,
    8. Kim K,
    9. Lee E, and
    10. Hong CC
    (2013) Selective small molecule targeting β-catenin function discovered by in vivo chemical genetic screen. Cell Rep 4:898–904.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Hart M,
    2. Concordet JP,
    3. Lassot I,
    4. Albert I,
    5. del los Santos R,
    6. Durand H,
    7. Perret C,
    8. Rubinfeld B,
    9. Margottin F,
    10. Benarous R, et al.
    (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207–210.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Hirai H,
    2. Matoba K,
    3. Mihara E,
    4. Arimori T, and
    5. Takagi J
    (2019) Crystal structure of a mammalian Wnt-frizzled complex. Nat Struct Mol Bio 26:372–379.
    OpenUrl
  56. ↵
    1. Holstein TW
    (2012) The evolution of the Wnt pathway. Cold Spring Harb Perspect Biol 4:a007922.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Holtzhausen A,
    2. Zhao F,
    3. Evans KS,
    4. Tsutsui M,
    5. Orabona C,
    6. Tyler DS, and
    7. Hanks BA
    (2015) Melanoma-derived Wnt5a promotes local dendritic-cell expression of Ido and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res 3:1082–1095.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Huang S-MA,
    2. Mishina YM,
    3. Liu S,
    4. Cheung A,
    5. Stegmeier F,
    6. Michaud GA,
    7. Charlat O,
    8. Wiellette E,
    9. Zhang Y,
    10. Wiessner S, et al.
    (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461:614–620.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Hwang W-L,
    2. Jiang J-K,
    3. Yang S-H,
    4. Huang T-S,
    5. Lan H-Y,
    6. Teng H-W,
    7. Yang C-Y,
    8. Tsai Y-P,
    9. Lin C-H,
    10. Wang H-W, et al.
    (2014) MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat Cell Biol 16:268–280.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Ilmer M,
    2. Boiles AR,
    3. Regel I,
    4. Yokoi K,
    5. Michalski CW,
    6. Wistuba II,
    7. Rodriguez J,
    8. Alt E, and
    9. Vykoukal J
    (2015) RSPO2 enhances canonical Wnt signaling to confer stemness-associated traits to susceptible pancreatic cancer cells. Cancer Res 75:1883–1896.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Ishitani T,
    2. Kishida S,
    3. Hyodo-Miura J,
    4. Ueno N,
    5. Yasuda J,
    6. Waterman M,
    7. Shibuya H,
    8. Moon RT,
    9. Ninomiya-Tsuji J, and
    10. Matsumoto K
    (2003) The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23:131–139.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Isobe T,
    2. Hisamori S,
    3. Hogan DJ,
    4. Zabala M,
    5. Hendrickson DG,
    6. Dalerba P,
    7. Cai S,
    8. Scheeren F,
    9. Kuo AH,
    10. Sikandar SS, et al.
    (2014) miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. eLife 3:e01977.
    OpenUrlCrossRefPubMed
  63. ↵
    1. James RG,
    2. Davidson KC,
    3. Bosch KA,
    4. Biechele TL,
    5. Robin NC,
    6. Taylor RJ,
    7. Major MB,
    8. Camp ND,
    9. Fowler K,
    10. Martins TJ, et al.
    (2012) WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling. PLoS One 7:e50457.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Janda CY,
    2. Waghray D,
    3. Levin AM,
    4. Thomas C, and
    5. Garcia KC
    (2012) Structural basis of Wnt recognition by Frizzled. Science 337:59–64.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Jiang J and
    2. Struhl G
    (1998) Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. Nature 391:493–496.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Jiang X,
    2. Hao H-X,
    3. Growney JD,
    4. Woolfenden S,
    5. Bottiglio C,
    6. Ng N,
    7. Lu B,
    8. Hsieh MH,
    9. Bagdasarian L,
    10. Meyer R, et al.
    (2013) Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 110:12649–12654.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Jimeno A,
    2. Gordon M,
    3. Chugh R,
    4. Messersmith W,
    5. Mendelson D,
    6. Dupont J,
    7. Stagg R,
    8. Kapoun AM,
    9. Xu L,
    10. Uttamsingh S, et al.
    (2017) A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin Cancer Res 23:7490–7497.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Jin Y,
    2. Ha N,
    3. Forés M,
    4. Xiang J,
    5. Gläßer C,
    6. Maldera J,
    7. Jiménez G, and
    8. Edgar BA
    (2015) EGFR/Ras signaling controls Drosophila intestinal stem cell proliferation via capicua-regulated genes. PLoS Genet 11:e1005634.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Kabiri Z,
    2. Greicius G,
    3. Madan B,
    4. Biechele S,
    5. Zhong Z,
    6. Zaribafzadeh H,
    7. Edison,
    8. Aliyev J,
    9. Wu Y,
    10. Bunte R, et al.
    (2014) Stroma provides an intestinal stem cell niche in the absence of epithelial Wnts. Development 141:2206–2215.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Kabiri Z,
    2. Greicius G,
    3. Zaribafzadeh H,
    4. Hemmerich A,
    5. Counter CM, and
    6. Virshup DM
    (2018) Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. J Clin Invest 128:3806–3812.
    OpenUrlCrossRef
  71. ↵
    1. Kabiri Z,
    2. Numata A,
    3. Kawasaki A,
    4. Edison,
    5. Tenen DG, and
    6. Virshup DM
    (2015) Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells. Blood 126:1086–1094.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Kakugawa S,
    2. Langton PF,
    3. Zebisch M,
    4. Howell S,
    5. Chang T-H,
    6. Liu Y,
    7. Feizi T,
    8. Bineva G,
    9. O’Reilly N,
    10. Snijders AP, et al.
    (2015) Notum deacylates Wnt proteins to suppress signalling activity. Nature 519:187–192.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Kikuchi A,
    2. Yamamoto H,
    3. Sato A, and
    4. Matsumoto S
    (2012) Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf) 204:17–33.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Kinzler KW,
    2. Nilbert MC,
    3. Vogelstein B,
    4. Bryan TM,
    5. Levy DB,
    6. Smith KJ,
    7. Preisinger AC,
    8. Hamilton SR,
    9. Hedge P,
    10. Markham A, et al.
    (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366–1370.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Ko AH,
    2. Chiorean EG,
    3. Kwak EL,
    4. Lenz HJ,
    5. Nadler PI,
    6. Wood DL,
    7. Fujimori M,
    8. Inada T,
    9. Kouji H, and
    10. McWilliams RR
    (2016) Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol 34 (15_suppl):e15721.
    OpenUrl
  76. ↵
    1. Koo B-K,
    2. Spit M,
    3. Jordens I,
    4. Low TY,
    5. Stange DE,
    6. van de Wetering M,
    7. van Es JH,
    8. Mohammed S,
    9. Heck AJR,
    10. Maurice MM, et al.
    (2012) Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488:665–669.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Korinek V,
    2. Barker N,
    3. Morin PJ,
    4. van Wichen D,
    5. de Weger R,
    6. Kinzler KW,
    7. Vogelstein B, and
    8. Clevers H
    (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784–1787.
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Lau T,
    2. Chan E,
    3. Callow M,
    4. Waaler J,
    5. Boggs J,
    6. Blake RA,
    7. Magnuson S,
    8. Sambrone A,
    9. Schutten M,
    10. Firestein R, et al.
    (2013) A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res 73:3132–3144.
    OpenUrlAbstract/FREE Full Text
  79. ↵
    1. Lee E,
    2. Ha S, and
    3. Logan SK
    (2015) Divergent androgen receptor and beta-catenin signaling in prostate cancer cells. PLoS One 10:e0141589.
    OpenUrl
  80. ↵
    1. Leung C,
    2. Tan SH, and
    3. Barker N
    (2018) Recent advances in Lgr5+ stem cell research. Trends Cell Biol 28:380–391.
    OpenUrlCrossRef
    1. Li B,
    2. Flaveny CA,
    3. Giambelli C,
    4. Fei DL,
    5. Han L,
    6. Hang BI,
    7. Bai F,
    8. Pei X-H,
    9. Nose V,
    10. Burlingame O, et al.
    (2014) Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One 9:e101969.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Li B,
    2. Orton D,
    3. Neitzel LR,
    4. Astudillo L,
    5. Shen C,
    6. Long J,
    7. Chen X,
    8. Kirkbride KC,
    9. Doundoulakis T,
    10. Guerra ML, et al.
    (2017) Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. Sci Signal 10:eaak9916.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Li C,
    2. Cao J,
    3. Zhang N,
    4. Tu M,
    5. Xu F,
    6. Wei S,
    7. Chen X, and
    8. Xu Y
    (2018) Identification of RSPO2 fusion mutations and target therapy using a porcupine inhibitor. Sci Rep 8:14244.
    OpenUrl
  83. ↵
    1. Li VSW,
    2. Ng SS,
    3. Boersema PJ,
    4. Low TY,
    5. Karthaus WR,
    6. Gerlach JP,
    7. Mohammed S,
    8. Heck AJR,
    9. Maurice MM,
    10. Mahmoudi T, et al.
    (2012) Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell 149:1245–1256.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Liu C,
    2. Kato Y,
    3. Zhang Z,
    4. Do VM,
    5. Yankner BA, and
    6. He X
    (1999) beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci USA 96:6273–6278.
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Liu C,
    2. Li Y,
    3. Semenov M,
    4. Han C,
    5. Baeg GH,
    6. Tan Y,
    7. Zhang Z,
    8. Lin X, and
    9. He X
    (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837–847.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Liu J,
    2. Pan S,
    3. Hsieh MH,
    4. Ng N,
    5. Sun F,
    6. Wang T,
    7. Kasibhatla S,
    8. Schuller AG,
    9. Li AG,
    10. Cheng D, et al.
    (2013) Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA 110:20224–20229.
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Loh KM,
    2. van Amerongen R, and
    3. Nusse R
    (2016) Generating cellular diversity and spatial form: Wnt signaling and the evolution of multicellular animals. Dev Cell 38:643–655.
    OpenUrlCrossRefPubMed
  88. ↵
    1. Luke JJ,
    2. Bao R,
    3. Sweis RF,
    4. Spranger S, and
    5. Gajewski TF
    (2019) WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res 25:3074–3083.
    OpenUrlAbstract/FREE Full Text
  89. ↵
    1. Ma W,
    2. Chen M,
    3. Kang H,
    4. Steinhart Z,
    5. Angers S,
    6. He X, and
    7. Kirschner MW
    (2019) Single molecule dynamics of Dishevelled at the plasma membrane and Wnt pathway activation. bioRxiv Available from: https://doi.org/10.1101/624882.
  90. ↵
    1. MacDonald BT,
    2. Hien A,
    3. Zhang X,
    4. Iranloye O,
    5. Virshup DM,
    6. Waterman ML, and
    7. He X
    (2014) Disulfide bond requirements for active Wnt ligands. J Biol Chem 289:18122–18136.
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. MacDonald BT,
    2. Tamai K, and
    3. He X
    (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26.
    OpenUrlCrossRefPubMed
  92. ↵
    1. Madan B,
    2. Harmston N,
    3. Nallan G,
    4. Montoya A,
    5. Faull P,
    6. Petretto E, and
    7. Virshup DM
    (2018) Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis. J Clin Invest 128:5620–5633.
    OpenUrlCrossRef
    1. Madan B,
    2. Ke Z,
    3. Harmston N,
    4. Ho SY,
    5. Frois AO,
    6. Alam J,
    7. Jeyaraj DA,
    8. Pendharkar V,
    9. Ghosh K,
    10. Virshup IH, et al.
    (2016a) Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene 35:2197–2207.
    OpenUrl
  93. ↵
    1. Madan B and
    2. Virshup DM
    (2015) Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs. Mol Cancer Ther 14:1087–1094.
    OpenUrlAbstract/FREE Full Text
  94. ↵
    1. Madan B,
    2. Walker MP,
    3. Young R,
    4. Quick L,
    5. Orgel KA,
    6. Ryan M,
    7. Gupta P,
    8. Henrich IC,
    9. Ferrer M,
    10. Marine S, et al.
    (2016b) USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds. Proc Natl Acad Sci USA 113:E2945–E2954.
    OpenUrlAbstract/FREE Full Text
  95. ↵
    1. Malanchi I,
    2. Peinado H,
    3. Kassen D,
    4. Hussenet T,
    5. Metzger D,
    6. Chambon P,
    7. Huber M,
    8. Hohl D,
    9. Cano A,
    10. Birchmeier W, et al.
    (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452:650–653.
    OpenUrlCrossRefPubMed
  96. ↵
    1. Mashima T,
    2. Taneda Y,
    3. Jang M-K,
    4. Mizutani A,
    5. Muramatsu Y,
    6. Yoshida H,
    7. Sato A,
    8. Tanaka N,
    9. Sugimoto Y, and
    10. Seimiya H
    (2017) mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget 8:47902–47915.
    OpenUrl
  97. ↵
    1. Mattes B,
    2. Dang Y,
    3. Greicius G,
    4. Kaufmann LT,
    5. Prunsche B,
    6. Rosenbauer J,
    7. Stegmaier J,
    8. Mikut R,
    9. Özbek S,
    10. Nienhaus GU, et al.
    (2018) Wnt/PCP controls spreading of Wnt/β-catenin signals by cytonemes in vertebrates. eLife 7.
  98. ↵
    1. McManus EJ,
    2. Sakamoto K,
    3. Armit LJ,
    4. Ronaldson L,
    5. Shpiro N,
    6. Marquez R, and
    7. Alessi DR
    (2005) Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 24:1571–1583.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Mi K,
    2. Dolan PJ, and
    3. Johnson GVW
    (2006) The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity. J Biol Chem 281:4787–4794.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Mikels AJ and
    2. Nusse R
    (2006) Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4:e115.
    OpenUrlCrossRefPubMed
  101. ↵
    1. Milanovic M,
    2. Fan DNY,
    3. Belenki D,
    4. Däbritz JHM,
    5. Zhao Z,
    6. Yu Y,
    7. Dörr JR,
    8. Dimitrova L,
    9. Lenze D,
    10. Monteiro Barbosa IA, et al.
    (2018) Senescence-associated reprogramming promotes cancer stemness. Nature 553:96–100.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Miyamoto DT,
    2. Zheng Y,
    3. Wittner BS,
    4. Lee RJ,
    5. Zhu H,
    6. Broderick KT,
    7. Desai R,
    8. Fox DB,
    9. Brannigan BW,
    10. Trautwein J, et al.
    (2015) RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349:1351–1356.
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Morin PJ,
    2. Sparks AB,
    3. Korinek V,
    4. Barker N,
    5. Clevers H,
    6. Vogelstein B, and
    7. Kinzler KW
    (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790.
    OpenUrlAbstract/FREE Full Text
  104. ↵
    1. Nagano H,
    2. Tomimaru Y,
    3. Eguchi H,
    4. Hama N,
    5. Wada H,
    6. Kawamoto K,
    7. Kobayashi S,
    8. Mori M, and
    9. Doki Y
    (2013) MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J Oncol 43:1066–1072.
    OpenUrlCrossRefPubMed
  105. ↵
    1. Nagaraj AB,
    2. Joseph P,
    3. Kovalenko O,
    4. Singh S,
    5. Armstrong A,
    6. Redline R,
    7. Resnick K,
    8. Zanotti K,
    9. Waggoner S, and
    10. DiFeo A
    (2015) Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget 6:23720–23734.
    OpenUrlCrossRef
  106. ↵
    1. Najdi R,
    2. Proffitt K,
    3. Sprowl S,
    4. Kaur S,
    5. Yu J,
    6. Covey TM,
    7. Virshup DM, and
    8. Waterman ML
    (2012) A uniform human Wnt expression library reveals a shared secretory pathway and unique signaling activities. Differentiation 84:203–213.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Nakamura Y,
    2. de Paiva Alves E,
    3. Veenstra GJC, and
    4. Hoppler S
    (2016) Tissue- and stage-specific Wnt target gene expression is controlled subsequent to β-catenin recruitment to cis-regulatory modules. Development 143:1914–1925.
    OpenUrlAbstract/FREE Full Text
  108. ↵
    1. Nandana S,
    2. Tripathi M,
    3. Duan P,
    4. Chu C-Y,
    5. Mishra R,
    6. Liu C,
    7. Jin R,
    8. Yamashita H,
    9. Zayzafoon M,
    10. Bhowmick NA, et al.
    (2017) Bone metastasis of prostate cancer can Be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Res 77:1331–1344.
    OpenUrlAbstract/FREE Full Text
  109. ↵
    1. Ng SS,
    2. Mahmoudi T,
    3. Danenberg E,
    4. Bejaoui I,
    5. de Lau W,
    6. Korswagen HC,
    7. Schutte M, and
    8. Clevers H
    (2009) Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J Biol Chem 284:35308–35313.
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Niehrs C
    (2012) The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 13:767–779.
    OpenUrlCrossRefPubMed
  111. ↵
    1. Nile AH and
    2. Hannoush RN
    (2019) Fatty acid recognition in the Frizzled receptor family. J Biol Chem 294:726–736.
    OpenUrlAbstract/FREE Full Text
  112. ↵
    1. Nishisho I,
    2. Nakamura Y,
    3. Miyoshi Y,
    4. Miki Y,
    5. Ando H,
    6. Horii A,
    7. Koyama K,
    8. Utsunomiya J,
    9. Baba S, and
    10. Hedge P
    (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665–669.
    OpenUrlAbstract/FREE Full Text
  113. ↵
    1. Nusse R,
    2. Brown A,
    3. Papkoff J,
    4. Scambler P,
    5. Shackleford G,
    6. McMahon A,
    7. Moon R, and
    8. Varmus H
    (1991) A new nomenclature for int-1 and related genes: the Wnt gene family. Cell 64:231.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Nusse R and
    2. Varmus HE
    (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31:99–109.
    OpenUrlCrossRefPubMed
  115. ↵
    1. Okada-Iwasaki R,
    2. Takahashi Y,
    3. Watanabe Y,
    4. Ishida H,
    5. Saito J,
    6. Nakai R, and
    7. Asai A
    (2016) The discovery and characterization of K-756, a novel Wnt/β-catenin pathway inhibitor targeting tankyrase. Mol Cancer Ther 15:1525–1534.
    OpenUrlAbstract/FREE Full Text
    1. Ong CK,
    2. Subimerb C,
    3. Pairojkul C,
    4. Wongkham S,
    5. Cutcutache I,
    6. Yu W,
    7. McPherson JR,
    8. Allen GE,
    9. Ng CCY,
    10. Wong BH, et al.
    (2012) Exome sequencing of liver fluke–associated cholangiocarcinoma. Nat Genet 44:690–693.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Piao S,
    2. Lee S-H,
    3. Kim H,
    4. Yum S,
    5. Stamos JL,
    6. Xu Y,
    7. Lee S-J,
    8. Lee J,
    9. Oh S,
    10. Han J-K, et al.
    (2008) Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. PLoS One 3:e4046.
    OpenUrlCrossRefPubMed
  117. ↵
    1. Picco G,
    2. Chen ED,
    3. Alonso LG,
    4. Behan FM,
    5. Gonçalves E,
    6. Bignell G,
    7. Matchan A,
    8. Fu B,
    9. Banerjee R,
    10. Anderson E, et al.
    (2019) Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nat Commun 10:2198.
    OpenUrl
  118. ↵
    1. Picco G,
    2. Petti C,
    3. Centonze A,
    4. Torchiaro E,
    5. Crisafulli G,
    6. Novara L,
    7. Acquaviva A,
    8. Bardelli A, and
    9. Medico E
    (2017) Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. EMBO Mol Med 9:293–303.
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. Posokhova E,
    2. Shukla A,
    3. Seaman S,
    4. Volate S,
    5. Hilton MB,
    6. Wu B,
    7. Morris H,
    8. Swing DA,
    9. Zhou M,
    10. Zudaire E, et al.
    (2015) GPR124 functions as a WNT7-specific coactivator of canonical β-catenin signaling. Cell Rep 10:123–130.
    OpenUrlCrossRefPubMed
  120. ↵
    1. Proffitt KD,
    2. Madan B,
    3. Ke Z,
    4. Pendharkar V,
    5. Ding L,
    6. Lee MA,
    7. Hannoush RN, and
    8. Virshup DM
    (2013) Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res 73:502–507.
    OpenUrlAbstract/FREE Full Text
  121. ↵
    1. Proffitt KD and
    2. Virshup DM
    (2012) Precise regulation of porcupine activity is required for physiological Wnt signaling. J Biol Chem 287:34167–34178.
    OpenUrlAbstract/FREE Full Text
  122. ↵
    1. Rathert P,
    2. Roth M,
    3. Neumann T,
    4. Muerdter F,
    5. Roe J-S,
    6. Muhar M,
    7. Deswal S,
    8. Cerny-Reiterer S,
    9. Peter B,
    10. Jude J, et al.
    (2015) Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525:543–547.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Reya T,
    2. Morrison SJ,
    3. Clarke MF, and
    4. Weissman IL
    (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111.
    OpenUrlCrossRefPubMed
  124. ↵
    1. Riffell JL,
    2. Lord CJ, and
    3. Ashworth A
    (2012) Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 11:923–936.
    OpenUrlCrossRefPubMed
  125. ↵
    1. Rijsewijk F,
    2. Schuermann M,
    3. Wagenaar E,
    4. Parren P,
    5. Weigel D, and
    6. Nusse R
    (1987) The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 50:649–657.
    OpenUrlCrossRefPubMed
  126. ↵
    1. Robey RW,
    2. Pluchino KM,
    3. Hall MD,
    4. Fojo AT,
    5. Bates SE, and
    6. Gottesman MM
    (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 18:452–464.
    OpenUrlCrossRefPubMed
  127. ↵
    1. Rubinfeld B,
    2. Albert I,
    3. Porfiri E,
    4. Fiol C,
    5. Munemitsu S, and
    6. Polakis P
    (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272:1023–1026.
    OpenUrlAbstract
    1. Ryland GL,
    2. Hunter SM,
    3. Doyle MA,
    4. Rowley SM,
    5. Christie M,
    6. Allan PE,
    7. Bowtell DDL,
    8. Gorringe KL,
    9. Campbell IG, and Australian Ovarian Cancer Study Group
    (2013) RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol 229:269–276.
    OpenUrl
  128. ↵
    1. Sánchez-Danés A,
    2. Larsimont J-C,
    3. Liagre M,
    4. Muñoz-Couselo E,
    5. Lapouge G,
    6. Brisebarre A,
    7. Dubois C,
    8. Suppa M,
    9. Sukumaran V,
    10. Del Marmol V, et al.
    (2018) A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature 562:434–438.
    OpenUrlCrossRefPubMed
  129. ↵
    1. Sato T,
    2. van Es JH,
    3. Snippert HJ,
    4. Stange DE,
    5. Vries RG,
    6. van den Born M,
    7. Barker N,
    8. Shroyer NF,
    9. van de Wetering M, and
    10. Clevers H
    (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469:415–418.
    OpenUrlCrossRefPubMed
  130. ↵
    1. Scarborough HA,
    2. Helfrich BA,
    3. Casás-Selves M,
    4. Schuller AG,
    5. Grosskurth SE,
    6. Kim J,
    7. Tan AC,
    8. Chan DC,
    9. Zhang Z,
    10. Zaberezhnyy V, et al.
    (2017) AZ1366: an inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin Cancer Res 23:1531–1541.
    OpenUrlAbstract/FREE Full Text
  131. ↵
    1. Schuijers J,
    2. Mokry M,
    3. Hatzis P,
    4. Cuppen E, and
    5. Clevers H
    (2014) Wnt-induced transcriptional activation is exclusively mediated by TCF/LEF. EMBO J 33:146–156.
    OpenUrlAbstract/FREE Full Text
  132. ↵
    1. Schwarz-Romond T,
    2. Fiedler M,
    3. Shibata N,
    4. Butler PJ,
    5. Kikuchi A,
    6. Higuchi Y, and
    7. Bienz M
    (2007) The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat Struct Mol Biol 14:484–492.
    OpenUrlCrossRefPubMed
  133. ↵
    1. Semenov MV,
    2. Habas R,
    3. Macdonald BT, and
    4. He X
    (2007) SnapShot: noncanonical Wnt signaling pathways. Cell 131:1378.
    OpenUrlPubMed
  134. ↵
    1. Seshagiri S,
    2. Stawiski EW,
    3. Durinck S,
    4. Modrusan Z,
    5. Storm EE,
    6. Conboy CB,
    7. Chaudhuri S,
    8. Guan Y,
    9. Janakiraman V,
    10. Jaiswal BS, et al.
    (2012) Recurrent R-spondin fusions in colon cancer. Nature 488:660–664.
    OpenUrlCrossRefPubMed
  135. ↵
    1. Shoshkes-Carmel M,
    2. Wang YJ,
    3. Wangensteen KJ,
    4. Tóth B,
    5. Kondo A,
    6. Massasa EE,
    7. Itzkovitz S, and
    8. Kaestner KH
    (2018) Subepithelial telocytes are an important source of Wnts that supports intestinal crypts. Nature 557:242–246.
    OpenUrlCrossRef
    1. Shultz MD,
    2. Cheung AK,
    3. Kirby CA,
    4. Firestone B,
    5. Fan J,
    6. Chen CH-T,
    7. Chin DN,
    8. Dipietro L,
    9. Fazal A,
    10. Feng Y, et al.
    (2013) Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem 56:6495–6511.
    OpenUrlCrossRefPubMed
  136. ↵
    1. Solberg NT,
    2. Waaler J,
    3. Lund K,
    4. Mygland L,
    5. Olsen PA, and
    6. Krauss S
    (2018) TANKYRASE inhibition enhances the antiproliferative effect of PI3K and EGFR inhibition, mutually affecting β-catenin and AKT signaling in colorectal cancer. Mol Cancer Res 16:543–553.
    OpenUrlAbstract/FREE Full Text
  137. ↵
    1. Solzak JP,
    2. Atale RV,
    3. Hancock BA,
    4. Sinn AL,
    5. Pollok KE,
    6. Jones DR, and
    7. Radovich M
    (2017) Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. NPJ Breast Cancer 3:17.
    OpenUrl
  138. ↵
    1. Spranger S,
    2. Bao R, and
    3. Gajewski TF
    (2015) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523:231–235.
    OpenUrlCrossRefPubMed
  139. ↵
    1. Staal FJT,
    2. Luis TC, and
    3. Tiemessen MM
    (2008) WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol 8:581–593.
    OpenUrlCrossRefPubMed
  140. ↵
    1. Steinhart Z,
    2. Pavlovic Z,
    3. Chandrashekhar M,
    4. Hart T,
    5. Wang X,
    6. Zhang X,
    7. Robitaille M,
    8. Brown KR,
    9. Jaksani S,
    10. Overmeer R, et al.
    (2017) Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med 23:60–68.
    OpenUrlCrossRefPubMed
    1. Storm EE,
    2. Durinck S,
    3. de Sousa e Melo F,
    4. Tremayne J,
    5. Kljavin N,
    6. Tan C,
    7. Ye X,
    8. Chiu C,
    9. Pham T,
    10. Hongo J-A, et al.
    (2016) Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature 529:97–100.
    OpenUrlCrossRef
  141. ↵
    1. Suzuki H,
    2. Watkins DN,
    3. Jair K-W,
    4. Schuebel KE,
    5. Markowitz SD,
    6. Chen WD,
    7. Pretlow TP,
    8. Yang B,
    9. Akiyama Y,
    10. Van Engeland M, et al.
    (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36:417–422.
    OpenUrlCrossRefPubMed
  142. ↵
    1. Swarup S and
    2. Verheyen EM
    (2012) Wnt/Wingless signaling in Drosophila. Cold Spring Harb Perspect Biol 4:a007930.
    OpenUrlAbstract/FREE Full Text
  143. ↵
    1. Taelman VF,
    2. Dobrowolski R,
    3. Plouhinec J-L,
    4. Fuentealba LC,
    5. Vorwald PP,
    6. Gumper I,
    7. Sabatini DD, and
    8. De Robertis EM
    (2010) Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143:1136–1148.
    OpenUrlCrossRefPubMed
  144. ↵
    1. Takada R,
    2. Satomi Y,
    3. Kurata T,
    4. Ueno N,
    5. Norioka S,
    6. Kondoh H,
    7. Takao T, and
    8. Takada S
    (2006) Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell 11:791–801.
    OpenUrlCrossRefPubMed
  145. ↵
    1. Taketo MM and
    2. Edelmann W
    (2009) Mouse models of colon cancer. Gastroenterology 136:780–798.
    OpenUrlCrossRefPubMed
  146. ↵
    1. Tammela T,
    2. Sánchez-Rivera FJ,
    3. Cetinbas NM,
    4. Wu K,
    5. Joshi NS,
    6. Helenius K,
    7. Park Y,
    8. Azimi R,
    9. Kerper NR,
    10. Wesselhoeft RA, et al.
    (2017) A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature 545:355–359.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Tang JY,
    2. Ally MS,
    3. Chanana AM,
    4. Mackay-Wiggan JM,
    5. Aszterbaum M,
    6. Lindgren JA,
    7. Ulerio G,
    8. Rezaee MR,
    9. Gildengorin G,
    10. Marji J, et al.
    (2016) Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17:1720–1731.
    OpenUrl
  148. ↵
    1. Tenbaum SP,
    2. Ordóñez-Morán P,
    3. Puig I,
    4. Chicote I,
    5. Arqués O,
    6. Landolfi S,
    7. Fernández Y,
    8. Herance JR,
    9. Gispert JD,
    10. Mendizabal L, et al.
    (2012) β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18:892–901.
    OpenUrlCrossRefPubMed
  149. ↵
    1. Thomson DW,
    2. Wagner AJ,
    3. Bantscheff M,
    4. Benson RE,
    5. Dittus L,
    6. Duempelfeld B,
    7. Drewes G,
    8. Krause J,
    9. Moore JT,
    10. Mueller K, et al.
    (2017) Discovery of a highly selective tankyrase inhibitor displaying growth inhibition effects against a diverse range of tumor derived cell lines. J Med Chem 60:5455–5471.
    OpenUrl
  150. ↵
    1. Thorne CA,
    2. Hanson AJ,
    3. Schneider J,
    4. Tahinci E,
    5. Orton D,
    6. Cselenyi CS,
    7. Jernigan KK,
    8. Meyers KC,
    9. Hang BI,
    10. Waterson AG, et al.
    (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat Chem Biol 6:829–836.
    OpenUrlCrossRefPubMed
  151. ↵
    1. Tolwinski NS,
    2. Wehrli M,
    3. Rives A,
    4. Erdeniz N,
    5. DiNardo S, and
    6. Wieschaus E
    (2003) Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Dev Cell 4:407–418.
    OpenUrlCrossRefPubMed
  152. ↵
    1. Topol L,
    2. Jiang X,
    3. Choi H,
    4. Garrett-Beal L,
    5. Carolan PJ, and
    6. Yang Y
    (2003) Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 162:899–908.
    OpenUrlAbstract/FREE Full Text
  153. ↵
    1. Trillsch F,
    2. Preinfalk V,
    3. Rahmeh M,
    4. Vogel M,
    5. Czogalla B,
    6. Burges A,
    7. Jeschke U, and
    8. Mahner S
    (2017) Inhibition of Wnt signaling as therapeutic option in platinum-resistant ovarian cancer. J Clin Oncol 35(15_suppl):e17050.
  154. ↵
    1. Tzeng H-E,
    2. Yang L,
    3. Chen K,
    4. Wang Y,
    5. Liu Y-R,
    6. Pan S-L,
    7. Gaur S,
    8. Hu S, and
    9. Yen Y
    (2015) The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget 6:11061–11073.
    OpenUrlCrossRefPubMed
  155. ↵
    1. Vanhollebeke B,
    2. Stone OA,
    3. Bostaille N,
    4. Cho C,
    5. Zhou Y,
    6. Maquet E,
    7. Gauquier A,
    8. Cabochette P,
    9. Fukuhara S,
    10. Mochizuki N, et al.
    (2015) Tip cell-specific requirement for an atypical Gpr124- and Reck-dependent Wnt/β-catenin pathway during brain angiogenesis. eLife 4:e06489.
    OpenUrlCrossRefPubMed
  156. ↵
    1. Veeck J,
    2. Niederacher D,
    3. An H,
    4. Klopocki E,
    5. Wiesmann F,
    6. Betz B,
    7. Galm O,
    8. Camara O,
    9. Dürst M,
    10. Kristiansen G, et al.
    (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25:3479–3488.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Veeck J,
    2. Noetzel E,
    3. Bektas N,
    4. Jost E,
    5. Hartmann A,
    6. Knüchel R, and
    7. Dahl E
    (2008) Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer 7:83.
    OpenUrlCrossRefPubMed
  158. ↵
    1. Vermeulen L,
    2. De Sousa E Melo F,
    3. van der Heijden M,
    4. Cameron K,
    5. de Jong JH,
    6. Borovski T,
    7. Tuynman JB,
    8. Todaro M,
    9. Merz C,
    10. Rodermond H, et al.
    (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468–476.
    OpenUrlCrossRefPubMed
  159. ↵
    1. Visvader JE and
    2. Lindeman GJ
    (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768.
    OpenUrlCrossRefPubMed
  160. ↵
    1. Voloshanenko O,
    2. Erdmann G,
    3. Dubash TD,
    4. Augustin I,
    5. Metzig M,
    6. Moffa G,
    7. Hundsrucker C,
    8. Kerr G,
    9. Sandmann T,
    10. Anchang B, et al.
    (2013) Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nat Commun 4:2610.
    OpenUrlPubMed
  161. ↵
    1. Waaler J,
    2. Machon O,
    3. Tumova L,
    4. Dinh H,
    5. Korinek V,
    6. Wilson SR,
    7. Paulsen JE,
    8. Pedersen NM,
    9. Eide TJ,
    10. Machonova O, et al.
    (2012) A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 72:2822–2832.
    OpenUrlAbstract/FREE Full Text
  162. ↵
    1. Waaler J,
    2. Machon O,
    3. von Kries JP,
    4. Wilson SR,
    5. Lundenes E,
    6. Wedlich D,
    7. Gradl D,
    8. Paulsen JE,
    9. Machonova O,
    10. Dembinski JL, et al.
    (2011) Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 71:197–205.
    OpenUrlAbstract/FREE Full Text
  163. ↵
    1. Wang G,
    2. Wang J, and
    3. Sadar MD
    (2008) Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 68:9918–9927.
    OpenUrlAbstract/FREE Full Text
  164. ↵
    1. Wang J,
    2. Sinha T, and
    3. Wynshaw-Boris A
    (2012) Wnt signaling in mammalian development: lessons from mouse genetics. Cold Spring Harb Perspect Biol 4:a007963.
    OpenUrlAbstract/FREE Full Text
  165. ↵
    1. Wang L,
    2. Dehm SM,
    3. Hillman DW,
    4. Sicotte H,
    5. Tan W,
    6. Gormley M,
    7. Bhargava V,
    8. Jimenez R,
    9. Xie F,
    10. Yin P, et al.
    (2018) A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol 29:352–360.
    OpenUrlCrossRefPubMed
  166. ↵
    1. Wang X,
    2. Reid Sutton V,
    3. Omar Peraza-Llanes J,
    4. Yu Z,
    5. Rosetta R,
    6. Kou Y-C,
    7. Eble TN,
    8. Patel A,
    9. Thaller C,
    10. Fang P, et al.
    (2007) Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. Nat Genet 39:836–838.
    OpenUrlCrossRefPubMed
  167. ↵
    1. Wang Y,
    2. He L,
    3. Du Y,
    4. Zhu P,
    5. Huang G,
    6. Luo J,
    7. Yan X,
    8. Ye B,
    9. Li C,
    10. Xia P, et al.
    (2015) The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 16:413–425.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Watson RL,
    2. Spalding AC,
    3. Zielske SP,
    4. Morgan M,
    5. Kim AC,
    6. Bommer GT,
    7. Eldar-Finkelman H,
    8. Giordano T,
    9. Fearon ER,
    10. Hammer GD, et al.
    (2010) GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia 12:357–365.
    OpenUrlCrossRefPubMed
  169. ↵
    1. Winston JT,
    2. Strack P,
    3. Beer-Romero P,
    4. Chu CY,
    5. Elledge SJ, and
    6. Harper JW
    (1999) The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 13:270–283.
    OpenUrlAbstract/FREE Full Text
  170. ↵
    1. Wong H-C,
    2. Bourdelas A,
    3. Krauss A,
    4. Lee H-J,
    5. Shao Y,
    6. Wu D,
    7. Mlodzik M,
    8. Shi D-L, and
    9. Zheng J
    (2003) Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 12:1251–1260.
    OpenUrlCrossRefPubMed
  171. ↵
    1. Wu G,
    2. Huang H,
    3. Garcia Abreu J, and
    4. He X
    (2009) Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One 4:e4926.
    OpenUrlCrossRefPubMed
  172. ↵
    1. Wu J,
    2. Jiao Y,
    3. Dal Molin M,
    4. Maitra A,
    5. de Wilde RF,
    6. Wood LD,
    7. Eshleman JR,
    8. Goggins MG,
    9. Wolfgang CL,
    10. Canto MI, et al.
    (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108:21188–21193.
    OpenUrlAbstract/FREE Full Text
  173. ↵
    1. Yamamoto TM,
    2. McMellen A,
    3. Watson ZL,
    4. Aguilera J,
    5. Ferguson R,
    6. Nurmemmedov E,
    7. Thakar T,
    8. Moldovan GL,
    9. Kim H,
    10. Cittelly DM, et al.
    (2019) Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog 58:1770–1782.
    OpenUrl
  174. ↵
    1. Yan HHN,
    2. Lai JCW,
    3. Ho SL,
    4. Leung WK,
    5. Law WL,
    6. Lee JFY,
    7. Chan AKW,
    8. Tsui WY,
    9. Chan ASY,
    10. Lee BCH, et al.
    (2017) RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut 66:1645–1656.
    OpenUrlAbstract/FREE Full Text
  175. ↵
    1. Yu J,
    2. Chia J,
    3. Canning CA,
    4. Jones CM,
    5. Bard FA, and
    6. Virshup DM
    (2014) WLS retrograde transport to the endoplasmic reticulum during Wnt secretion. Dev Cell 29:277–291.
    OpenUrlCrossRefPubMed
  176. ↵
    1. Yu J,
    2. Tao Q,
    3. Cheng YY,
    4. Lee KY,
    5. Ng SSM,
    6. Cheung KF,
    7. Tian L,
    8. Rha SY,
    9. Neumann U,
    10. Röcken C, et al.
    (2009) Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 115:49–60.
    OpenUrlCrossRefPubMed
  177. ↵
    1. Zeng X,
    2. Huang H,
    3. Tamai K,
    4. Zhang X,
    5. Harada Y,
    6. Yokota C,
    7. Almeida K,
    8. Wang J,
    9. Doble B,
    10. Woodgett J, et al.
    (2008) Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135:367–375.
    OpenUrlAbstract/FREE Full Text
  178. ↵
    1. Zeng X,
    2. Tamai K,
    3. Doble B,
    4. Li S,
    5. Huang H,
    6. Habas R,
    7. Okamura H,
    8. Woodgett J, and
    9. He X
    (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438:873–877.
    OpenUrlCrossRefPubMed
  179. ↵
    1. Zhan T,
    2. Rindtorff N, and
    3. Boutros M
    (2017) Wnt signaling in cancer. Oncogene 36:1461–1473.
    OpenUrlCrossRefPubMed
  180. ↵
    1. Zhao F,
    2. Xiao C,
    3. Evans KS,
    4. Theivanthiran T,
    5. DeVito N,
    6. Holtzhausen A,
    7. Liu J,
    8. Liu X,
    9. Boczkowski D,
    10. Nair S, et al.
    (2018) Paracrine wnt5a-β-catenin signaling triggers a metabolic program that drives dendritic cell tolerization. Immunity 48:147–160.e7.
    OpenUrlCrossRefPubMed
  181. ↵
    1. Zhong Z,
    2. Sepramaniam S,
    3. Chew XH,
    4. Wood K,
    5. Lee MA,
    6. Madan B, and
    7. Virshup DM
    (2019) PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene 38:6662–6677.
    OpenUrl
  182. ↵
    1. Zhou Y and
    2. Nathans J
    (2014) Gpr124 controls CNS angiogenesis and blood-brain barrier integrity by promoting ligand-specific canonical wnt signaling. Dev Cell 31:248–256.
    OpenUrlCrossRefPubMed
  183. ↵
    1. Zhu J,
    2. Zhang S,
    3. Gu L, and
    4. Di W
    (2012) Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma. Carcinogenesis 33:2334–2343.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 97 (2)
Molecular Pharmacology
Vol. 97, Issue 2
1 Feb 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Wnt Signaling and Drug Resistance in Cancer
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Section on New Opportunities in Targeting WNT Signaling – Minireview

Wnt Signaling and Drug Resistance in Cancer

Zheng Zhong and David M. Virshup
Molecular Pharmacology February 1, 2020, 97 (2) 72-89; DOI: https://doi.org/10.1124/mol.119.117978

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleSpecial Section on New Opportunities in Targeting WNT Signaling – Minireview

Wnt Signaling and Drug Resistance in Cancer

Zheng Zhong and David M. Virshup
Molecular Pharmacology February 1, 2020, 97 (2) 72-89; DOI: https://doi.org/10.1124/mol.119.117978
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Wnt Signaling Pathway
    • Aberrant Wnt Signaling in Cancer and Pharmacological Targeting of Wnt Signaling
    • Wnt Signaling Mediated Resistance in Cancer Therapy
    • Resistance to Wnt Pathway Blockade in Normal Tissue and Wnt-Driven Cancer
    • Concluding Remarks
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Class F Receptors as Molecular Machines
  • WNT Signaling in Cardiomyocyte Proliferation
Show more Special Section on New Opportunities in Targeting WNT Signaling – Minireview

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics